SNO | Package Name | Category | A1 | A2 | A3 | A4 | A5 | A6 | S1 | S2 |
---|---|---|---|---|---|---|---|---|---|---|
123 | CMU0106 : BREAST CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
124 | CMU0106 -a : BREAST CANCER - COMBINED REGIMEN AC & T | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
125 | CMU0106 -a-I : BREAST CANCER - DOSE DENSE AC (ADRIAMYCIN/CYCLOPHOSPHAMIDE) ; (DAY 1 - DOXORUBICIN 60MG/M2 IV, CYCLOPHOSPHAMIDE 600MG/M2 IV) ; REPEAT CYCLE - EVERY 14 DAYS FOR 4 CYCLES; FOLLOWED BY PACLITAXEL FOR 4 CYCLES | MEDICAL ONCOLOGY | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 |
126 | CMU0106 -a-II : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 175MG/M2) REPEAT CYCLE - EVERY 14 DAYS FOR 4 CYCLES | MEDICAL ONCOLOGY | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 |
127 | CMU0106 -a-III : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 175MG/M2) REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLES | MEDICAL ONCOLOGY | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 |
128 | CMU0106 -a-IV : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 80MG/M2) REPEAT CYCLE - WEEKLY FOR 12 CYCLES | MEDICAL ONCOLOGY | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 |
129 | CMU0106 -b : BREAST CANCER - TC (DOECTAXEL & CYCLOPHOSPHAMIDE) ; DAY 1 - DOCETAXEL 75MG/M2 IV, CYCLOPHOSPHAMIDE 600MG/M2 IV ; REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLES | MEDICAL ONCOLOGY | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 |
130 | CMU0106 -c : BREAST CANCER - CMF (CYCLOPHOSPHAMIDE/METHOTREXATE/FLUOROURACIL) - (INCLUDES DAY 1 & DAY 8) ; DAYS 1-14 - CYCLOPHOSPHAMIDE 100MG/M2 ORALLY ; DAYS 1 AND 8 - METHOTREXATE 40MG/M2 IV ; DAYS 1 AND 8 - 5-FLUOROURACIL 600MG/M2 IV. ; REPEAT CYCLE - EVERY 28 DAYS FOR 6 CYCLES | MEDICAL ONCOLOGY | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 |
131 | CMU0106 -d : BREAST CANCER - EC (EPIRUBICIN/CYCLOPHOSPHAMIDE) ; DAY 1 - EPIRUBICIN 100MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 830MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 8 CYCLES | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
132 | CMU0106 -e : BREAST CANCER - FEC + T | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
133 | CMU0106 -e-I : BREAST CANCER - FEC/CEF FOLLOWED BY T (FLUOROURACIL/EPIRUBICIN/CYCLOPHOSPHAMIDE) - FOLLOWED BY DOCETAXEL OR FOLLOWED BY WEEKLY PACLITAXEL) ; DAY 1 - 5-FLUOROURACIL 500MG/M2 IV ; DAY 1 - EPIRUBICIN 100MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
134 | CMU0106 -e-II : BREAST CANCER - DOCETAXEL - (PRECEEDED BY FEC/CEF ) ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 3 CYCLES | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
135 | CMU0106 -e-III : BREAST CANCER - PACLITAXEL - WEEKLY - (PRECEEDED BY FEC/CEF ) ; PACLITAXEL 100MG/M2 IV ; REPEAT CYCLE - ONCE WEEKLY FOR 8 WEEKS | MEDICAL ONCOLOGY | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 |
136 | CMU0106 -f : BREAST CANCER - FAC + T | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
137 | CMU0106 -f-I : BREAST CANCER - FAC FOLLOWED BY T (FLUOROURACIL/ADRIAMYCIN/CYCLOPHOSPHAMIDE) - FOLLOWED BY WEEKLY PACLITAXEL ; 5-FLUOROURACIL 500MG/M2 IV DAYS 1 AND 8 OR 1 AND 4 - ; DAY 1 - DOXORUBICIN 50MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 6 CYCLES | MEDICAL ONCOLOGY | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 |
138 | CMU0106 -f-II : BREAST CANCER - PACLITAXEL - WEEKLY - PRECEEDED BY FAC ; PACLITAXEL 80MG/M2 IV ; REPEAT CYCLE WEEKLY FOR 12 WEEKS. | MEDICAL ONCOLOGY | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 |
139 | CMU0106 -g : BREAST CANCER - TAC (DOCETAXEL/ADRIAMYCIN/CYCLOPHOSPHAMIDE) ; DAY 1 - DOXORUBICIN 60MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, | MEDICAL ONCOLOGY | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 |
140 | CMU0106 -h : BREAST CANCER - AC FOLLOWED BY T + TRASTUZUMAB | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
141 | CMU0106 -h-I : BREAST CANCER - AC - FOLLOWED BY PACLITAXEL + TRASTUZUMAB +/- PERTUZUMAB ; DAY 1 - DOXORUBICIN 60MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLE | MEDICAL ONCOLOGY | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 |
142 | CMU0106 -h-II : BREAST CANCER - PACLITAXEL (PRECEEDED BY AC) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; PACLITAXEL 80MG/M2 IV. ; REPEAT CYCLE WEEKLY FOR 12 WEEKS. | MEDICAL ONCOLOGY | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 |
143 | CMU0106 -h-III : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; REPEAT CYCLE EVERY 21 DAYS TO COMPLETE 1 YEAR. ; (TO BE APPROVED WITH PACLITAXEL CYCLE 1, 4, 7, 10 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
144 | CMU0106 -h-IV : BREAST CANCER - TRASTUZUMAB 4MG (FOLLOWED BY TRASTUZUMAB 2MG SUBSEQUENT WEEKS) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 4MG/KG IV WITH FIRST DOSE OF PACLITAXEL. ; (FIRST DOSE - ONLY TO BE APPROVED WITH PACLITAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
145 | CMU0106 -h-V : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 2MG/KG IV WEEKLY TILL ONE YEAR FROM DAY 1 OF AC. ; (TO BE APPROVED WITH PACLITAXEL CYCLES 2 - 12 AND STANDALONE FOR THE UPTO 1 YEAR EVERY WEEK) | MEDICAL ONCOLOGY | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 |
146 | CMU0106 -i : BREAST CANCER - TCH | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
147 | CMU0106 -i-I : BREAST CANCER - TC (DOCETAXEL/CARBOPLATIN) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 75MG/M2 IV; CARBOPLATIN AUC 6MG PER MIN/ML IV. ; EVERY 21 DAYS FOR 6 CYCLES | MEDICAL ONCOLOGY | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 |
148 | CMU0106 -i-II : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH TC PACKAGE) ; TRASTUZUMAB 6MG/KG IV ; REPEAT CYCLE EVERY 21 DAYS TO COMPLETE 1 YEAR. ; (TO BE APPROVED WITH TC CYCLE 1 TO 6 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 18 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
149 | CMU0106 -i-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH TC PACKAGE) ; DAY 1 - TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH TC CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
150 | CMU0106 -i-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES - WEEKLY) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 17 WEEEKS MAY OVERLAP WITH TC CYCLES 2 - 6. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR | MEDICAL ONCOLOGY | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 |
151 | CMU0106 -j : BREAST CANCER - AC FOLLOWED BY DOCETAXEL + TRASTUZUMAB | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
152 | CMU0106 -j-I : BREAST CANCER - AC - FOLLOWED BY DOCETAXEL + TRASTUZUMAB ; DAY 1 - DOXORUBICIN 60MG/M2 IV; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, | MEDICAL ONCOLOGY | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 |
153 | CMU0106 -j-II : BREAST CANCER - DOCETAXEL (PRECEEDED BY AC) + TRASTUZUMAB ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES | MEDICAL ONCOLOGY | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 |
154 | CMU0106 -j-III : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH DOCETAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; REPEAT EVERY 21 DAYS TILL 1 YEAR ; (TO BE APPROVED WITH DOCETAXEL CYCLE 1 TO 4 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) OR FROM 13 TH WEEK AFTER COMPLETION OF 12 WEEKS OF WEEKLY TRASTUZUMAB - UPTO 1 YEAR EVERY 21 DAYS) | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
155 | CMU0106 -j-IV : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH DOCETAXEL PACKAGE) ; TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH DOCETAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
156 | CMU0106 -j-V : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 11 WEEEKS MAY OVERLAP WITH DOCETAXEL CYCLES 2 - 4. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR) | MEDICAL ONCOLOGY | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 |
157 | CMU0106 -k : BREAST CANCER - DOCETAXEL + CYCLOPHOSPHAMIDE + TRASTUZUMAB | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
158 | CMU0106 -k-I : BREAST CANCER - DOCETAXEL + CYCLOPHOSPHAMIDE - WITH TRASTUZUMAB ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 75MG/M2 IV; CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, | MEDICAL ONCOLOGY | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 |
159 | CMU0106 -k-II : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH DOCETAXEL + CYCLOPHOSPHAMIDE PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; (TO BE APPROVED WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLE 1 TO 4 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 12 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
160 | CMU0106 -k-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH DOCETAXEL + CYCLOPHOSPHAMIDE PACKAGE) ; TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
161 | CMU0106 -k-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 11 WEEEKS MAY OVERLAP WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLES 2 - 4. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR) | MEDICAL ONCOLOGY | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 |
162 | CMU0106 -L : BREAST CANCER - PACLITAXEL + TRASTUZUMAB | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
163 | CMU0106 -L-I : BREAST CANCER - PACLITAXEL - (WITH TRASTUZUMAB) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; PACLITAXEL 80MG/M2 IV. ; REPEAT CYCLE WEEKLY FOR 12 WEEKS. | MEDICAL ONCOLOGY | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 |
164 | CMU0106 -L-II : BREAST CANCER - TRASTUZUMAB (6MG) ; TRASTUZUMAB 6MG/KG IV ; REPEAT EVERY 21 DAYS ; (TO BE APPROVED AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 12 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
165 | CMU0106 -L-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; TRASTUZUMAB 4MG/KG IV WITH FIRST DOSE OF PACLITAXEL. ; (FIRST DOSE - ONLY TO BE APPROVED WITH PACLITAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
166 | CMU0106 -L-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 2MG/KG IV WEEKLY ; (TO BE APPROVED WITH PACLITAXEL CYCLES 2 - 12. MAY BE APPROVED AS STANDALONE FOR THE UPTO 1 YEAR EVERY WEEK OR TRASTUZUMAB 6MG PACKAGE MAY BE USED ONCE EVERY 21 DAYS UPTO 1 YEAR) | MEDICAL ONCOLOGY | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 |
167 | CMU0106 -N : BREAST CANCER - TAMOXIFEN | MEDICAL ONCOLOGY | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
168 | CMU0106 -O : BREAST CANCER - AROMATASE INHIBITORS | MEDICAL ONCOLOGY | 1100 | 1100 | 1100 | 1100 | 1100 | 1100 | 1100 | 1100 |
169 | CMU0106 -P : BREAST CANCER - ZOLEDRONIC ACID FOR SKELETAL METASTASIS | MEDICAL ONCOLOGY | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 |
170 | CMU0107 : BLADDER CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
171 | CMU0107 -a-I : BLADDER CANCER - DDMVAC ; DAY 1 - METHOTREXATE 30MG/M2 IV; DAY 2 - VINBLASTINE 3MG/M2 IV, DOXORUBICIN 30MG/M2 IV, CISPLATIN 70MG/M2 IV; ; REPEAT EVERY 2 WEEKS FOR 3-4 CYCLES | MEDICAL ONCOLOGY | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 |
172 | CMU0107 -a-II : BLADDER CANCER - GEMCITABINE + CISPLATIN ; DAYS 1, 8, AND 15 - GEMCITABINE 1, 000MG/M2 IV; DAY 2 - CISPLATIN 70MG/M2. ; REPEAT EVERY 4 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 |
173 | CMU0107 -a-III : BLADDER CANCER - CISPLATIN + METHOTREXATE + VINBLASTINE (CMV) ; DAY 1 - METHOTREXATE 30MG/M2 IV, VINBLASTINE 4MG/M2 IV; DAY 2 - CISPLATIN 100MG/M2 IV, LEUCOVORIN 15MG ORAL OR IV EVERY 6 HOURS FOR 4 DOSES; DAY 8 - METHOTREXATE 30MG/M2 IV, VINBLASTINE 4MG/M2 IV DAY 9 - LEUCOVORIN 15MG ORAL EVERY 6 HOURS FOR 4 DOSES ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. | MEDICAL ONCOLOGY | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 |
174 | CMU0107 -a-IV : BLADDER CANCER - RADIOSENSITIZING - CISPLATINC + 5-FU ; DAYS 1, 2, 3, 15, 16, AND 17 - IV HYDRATION AT A RATE OF 500ML/HOUR; FOLLOWED BY 5-FU 400MG/M2 IV PUSH; FOLLOWED BY CISPLATIN 15MG/M2 IV OVER 1 HOUR AS INDUCTION AND CONSOLIDATION THERAPY | MEDICAL ONCOLOGY | 10300 | 10300 | 10300 | 10300 | 10300 | 10300 | 10300 | 10300 |
175 | CMU0107 -a-V : BLADDER CANCER -RADIOSENSITIZING - CISPLATIN + PACLITAXEL ; DAYS 1, 8, AND 15 - PACLITAXEL 50MG/M2 ; DAY 1-3, 8-10, 15-17 - CISPLATIN 15MG/M2; FOLLOWED BY TWICE-DAILY RADIOTHERAPY FOR 8 DAYS | MEDICAL ONCOLOGY | 19300 | 19300 | 19300 | 19300 | 19300 | 19300 | 19300 | 19300 |
176 | CMU0107 -a-VI : BLADDER CANCER -RADIOSENSITIZING - 5-FU + MITOMYCIN32 ; DAY 1 OF RADIOTHERAPY - MITOMYCIN 12MG/M2 IV BOLUS, PLUS ; WEEK 1 (FRACTIONS 1-5) AND WEEK 4 (FRACTIONS 16-20) OF RADIOTHERAPY - 5-FU 500MG/M2 CONTINUOUS IV INFUSION (10 DAYS TOTAL) | MEDICAL ONCOLOGY | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 |
177 | CMU0107 -c : BLADDER CANCER - CONCURRENT CISPLATIN; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 5 CYCLES | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
178 | CMU0108 : LUNG CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
179 | CMU0108 -i : LUNG CANCER - MESOTHELIOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
180 | CMU0108 -i-a : LUNG CANCER - MESOTHELIOMA - PEMETREXED + CISPLATIN ; DAY 1 - PEMETREXED 500MG/M2 IV, CISPLATIN 75MG/M2 ; REPEAT EVERY 21 DAYS UP TO 12 CYCLES. | MEDICAL ONCOLOGY | 15200 | 15200 | 15200 | 15200 | 15200 | 15200 | 15200 | 15200 |
181 | CMU0108 -i-b : LUNG CANCER - MESOTHELIOMA - PEMETREXED + CARBOPLATIN ; DAY 1 - PEMETREXED 500MG/M2 IV, CARBOPLATIN AUC 5MG/MIN/ML IV. ; REPEAT EVERY 21 DAYS FOR A MAX OF 9 CYCLES. | MEDICAL ONCOLOGY | 17300 | 17300 | 17300 | 17300 | 17300 | 17300 | 17300 | 17300 |
182 | CMU0108 -i-c : LUNG CANCER - MESOTHELIOMA - CISPLATIN & GEMCITABINE ; DAY 1 - CISPLATIN 80-100MG/M2 IV ; DAYS 1, 8, AND 15 - GEMCITABINE 1000-1250MG/M2 IV ; REPEAT EVERY 21 - 28 DAYS FOR 6 CYCLES. | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
183 | CMU0108 -i-d : LUNG CANCER - MESOTHELIOMA - VINORELBINE ; VINORELBINE 25-30MG/M2 (MAX 60MG) IV ; REPEAT EVERY WEEK FOR 12 WEEKS. | MEDICAL ONCOLOGY | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 |
184 | CMU0108 -i-e : LUNG CANCER - MESOTHELIOMA - PEMETREXED ; DAY 1 - PEMETREXED 500MG/M2 IV. ; REPEAT EVERY 21 DAYS FOR 4 CYCLES (IF FIRST LINE) OR REPEAT EVERY 21 DAYS FOR 8 CYCLES (IF SECOND LINE) | MEDICAL ONCOLOGY | 15200 | 15200 | 15200 | 15200 | 15200 | 15200 | 15200 | 15200 |
185 | CMU0108 -i-f : LUNG CANCER - MESOTHELIOMA - GEMCITABINE ; DAYS 1, 8, AND 15 - GEMCITABINE 1250MG/M2 IV. ; REPEAT EVERY 28 DAYS FOR A MAX OF 10 CYCLES. | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
186 | CMU0108 -ii : LUNG CANCER - NSCLC | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
187 | CMU0108 -ii-a : LUNG CANCER - NSCLC - CISPLATIN & VINORELBINE - (I) ; DAYS 1 AND 8 - CISPLATIN 50MG/M2 IV AND DAYS 1, 8, 15 AND 22 - VINORELBINE 25MG/M2 IV ; (OR) ; DAY 1 - CISPLATIN 100MG/M2 IV AND DAYS 1, 8, 15 AND 22 - VINORELBINE 30MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 35300 | 35300 | 35300 | 35300 | 35300 | 35300 | 35300 | 35300 |
188 | CMU0108 -ii-b : LUNG CANCER - NSCLC - CISPLATIN & VINORELBINE - (II) ; DAY 1 - CISPLATIN 75-80MG/M2 ; DAYS 1 AND 8 - VINORELBINE 25-30MG/M2. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES | MEDICAL ONCOLOGY | 18800 | 18800 | 18800 | 18800 | 18800 | 18800 | 18800 | 18800 |
189 | CMU0108 -ii-c : LUNG CANCER - NSCLC - CISPLATIN & ETOPOSIDE ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES | MEDICAL ONCOLOGY | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 |
190 | CMU0108 -ii-d : LUNG CANCER - NSCLC - CISPLATIN & DOCETAXEL ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 |
191 | CMU0108 -ii-e : LUNG CANCER - NSCLC - CISPLATIN & GEMCITABINE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 1 AND 8 - GEMCITABINE 1, 250MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES | MEDICAL ONCOLOGY | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 |
192 | CMU0108 -ii-f : LUNG CANCER - NSCLC - PEMETREXED + CISPLATIN (FOR NON SQUAMOUS CELL CA) ; DAY 1 - CISPLATIN 75MG/M2 IV, PEMETREXED 500MG/M2 IV. ; REPEAT EVERY - 21 DAYS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 15200 | 15200 | 15200 | 15200 | 15200 | 15200 | 15200 | 15200 |
193 | CMU0108 -ii-g : LUNG CANCER - NSCLC - PACLITAXEL/CARBOPLATIN ; DAY 1 - PACLITAXEL 200MG/M2 IV, CARBOPLATIN AUC 6MG PER MIN/ML IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 8500 | 8500 | 8500 | 8500 | 8500 | 8500 | 8500 | 8500 |
194 | CMU0108 -ii-h : LUNG CANCER - NSCLC - CISPLATIN & ETOPOSIDE ; DAYS 1, 8, 29 AND 36 - CISPLATIN 50MG/M2 IV ; DAYS 1-5 AND 29-33 - ETOPOSIDE 50MG/M2 IV ; CONCURRENT THORACIC RADIOTHERAPY 1.8GY/DAY FOR 5 DAYS/WEEK (TOTAL DOSE, 61GY). | MEDICAL ONCOLOGY | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 |
195 | CMU0108 -iii : LUNG CANCER - SCLC | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
196 | CMU0108 -ii-i : LUNG CANCER - NSCLC - CISPLATIN & VINBLASTINE ; DAYS 1 AND 29 - CISPLATIN 100MG/M2 IV ; DAYS 1, 8, 15, 22 AND 29 - VINBLASTINE 5MG/M2 IV ; CONCURRENT THORACIC RADIOTHERAPY (TOTAL DOSE, 60GY). | MEDICAL ONCOLOGY | 8600 | 8600 | 8600 | 8600 | 8600 | 8600 | 8600 | 8600 |
197 | CMU0108 -iii-a : LUNG CANCER - SCLC - CISPLATIN & ETOPOSIDE ; DAY 1 - CISPLATIN 60MG/M2 IV, DAYS 1-3 - ETOPOSIDE 120MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR AT LEAST 4 CYCLES. ;(OR) ; DAY 1 - CISPLATIN 80MG/M2 IV, DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4-6 CYCLES. | MEDICAL ONCOLOGY | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 |
198 | CMU0108 -iii-b : LUNG CANCER - SCLC - CARBOPLATIN & ETOPOSIDE ; DAY 1 - CARBOPLATIN AUC 5-6MG PER MIN/ML IV ; DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS OR 28 DAYS FOR 4 - 6 CYCLES | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
199 | CMU0108 -iii-c : LUNG CANCER - SCLC - CISPLATIN + IRINOTECAN ; DAY 1 - CISPLATIN 60MG/M2 IV. ; DAYS 1, 8, AND 15 - IRINOTECAN 60MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 |
200 | CMU0108 -iii-d : LUNG CANCER - SCLC - CISPLATIN + IRINOTECAN ; DAY 1 AND 8 - CISPLATIN 30MG/M2 IV, IRINOTECAN 65MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4-6 CYCLES. | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
201 | CMU0108 -iii-e : LUNG CANCER - SCLC - CARBOPLATIN & IRINOTECAN ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAYS 1, 8, AND 15 - IRINOTECAN 50MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES | MEDICAL ONCOLOGY | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 |
202 | CMU0108 -ii-j : LUNG CANCER - NSCLC - CARBOPLATIN + PEMETREXED ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAY 1 - PEMETREXED 500 MG/M2 IV ; WITH CONCURRENT THORACIC RADIOTHERAPY. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 17300 | 17300 | 17300 | 17300 | 17300 | 17300 | 17300 | 17300 |
203 | CMU0108 -ii-k : LUNG CANCER - NSCLC - CISPLATIN + PEMETREXED ; DAY 1 - CISPLATIN 75 MG/M2 IV. ; DAY 1 - PEMETREXED 500 MG/M2 IV ; WITH CONCURRENT THORACIC RADIOTHERAPY. ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. | MEDICAL ONCOLOGY | 15700 | 15700 | 15700 | 15700 | 15700 | 15700 | 15700 | 15700 |
204 | CMU0108 -ii-l : LUNG CANCER - NSCLC - PACLITAXEL + CARBOPLATIN ; PACLITAXEL 45MG/M2 IV + CARBOPLATIN AUC 2MG PER MIN/ML IV ; WITH CONCURRENT THORACIC RADIOTHERAPY (TOTAL DOSE, 60GY) ; REPEAT WEEKLY FOR 6 WEEKS | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
205 | CMU0109 : OESOPHAGEAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
206 | CMU0109 -i : ESOPHAGEAL CANCER - NEO ADJUVANT | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
207 | CMU0109 -i-a : ESOPHAGEAL CANCER - NEO ADJUVANT - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV + CARBOPLATIN AUC 2MG/MIN/ML IV. ; REPEAT WEEKLY FOR 5 WEEKS | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
208 | CMU0109 -i-b : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & CISPLATIN ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV. | MEDICAL ONCOLOGY | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 |
209 | CMU0109 -i-c : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & CISPLATIN ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 AND DAYS 22-26 - 5-FU 800 MG/M2 IV ; REPEAT EVERY 21 DAYS FOR 2 CYCLES | MEDICAL ONCOLOGY | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 |
210 | CMU0109 -i-d : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL + OXALIPLATIN + LEUCOVORIN ; DAY 1 - OXALIPLATIN 85MG/M2, LEUCOVORIN 200MG/M2 AND 5-FU 400MG/M2 BOLUS, WITH 1, 600MG/M2 INFUSION; ; REPEAT EVERY 14 DAYS FOR 6 CYCLES | MEDICAL ONCOLOGY | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 |
211 | CMU0109 -i-e : ESOPHAGEAL CANCER - NEO ADJUVANT - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE WEEKLY FOR 5 WEEKS | MEDICAL ONCOLOGY | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 |
212 | CMU0109 -i-f : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & OXALIPLATIN ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY IV | MEDICAL ONCOLOGY | 27100 | 27100 | 27100 | 27100 | 27100 | 27100 | 27100 | 27100 |
213 | CMU0109 -i-g : ESOPHAGEAL CANCER - NEO ADJUVANT - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 |
214 | CMU0109 -i-h : ESOPHAGEAL CANCER - NEO ADJUVANT - IRINOTECAN & CISPLATIN ; DAYS 1, 8, 22, AND 29 - IRINOTECAN 65MG/M2 IV, CISPLATIN 30MG/M2 IV. | MEDICAL ONCOLOGY | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 |
215 | CMU0109 -ii : ESOPHAGEAL CANCER - PERI-OPERATIVE | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
216 | CMU0109 -i-i : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45MG/M2 IV ; DAYS 1-5 - 5-FU 300MG/M2/DAY IV INFUSION. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
217 | CMU0109 -ii-a : ESOPHAGEAL CANCER - PERI-OPERATIVE - ECF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; CISPLATIN 60MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV CONTINUOUS INFUSION ONCE DAILY; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY | MEDICAL ONCOLOGY | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 |
218 | CMU0109 -ii-b : ESOPHAGEAL CANCER - PERI-OPERATIVE - EOF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. | MEDICAL ONCOLOGY | 19700 | 19700 | 19700 | 19700 | 19700 | 19700 | 19700 | 19700 |
219 | CMU0109 -ii-c : ESOPHAGEAL CANCER - PERI-OPERATIVE - EOC (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. | MEDICAL ONCOLOGY | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 |
220 | CMU0109 -ii-d : ESOPHAGEAL CANCER - PERI-OPERATIVE - FLUOROURACIL & CISPLATIN ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV ; REPEAT CYCLE EVERY 28 DAYS FOR 2-4 CYCLES | MEDICAL ONCOLOGY | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 |
221 | CMU0109 -ii-e : ESOPHAGEAL CANCER - PERI-OPERATIVE - FLUOROURACIL & CISPLATIN ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 - 5-FU 800 MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS. ; CYCLED EVERY 21 DAYS FOR 2 CYCLESCYCLED EVERY 21 DAYS FOR 2 CYCLES | MEDICAL ONCOLOGY | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 |
222 | CMU0109 -iii : ESOPHAGEAL CANCER - POST-OPERATIVE | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
223 | CMU0109 -iii-a : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACIL + LEUCOVORIN (I) ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV, FOLLOWED BY 4 WEEKS BREAK AND CCRT ; RT DAYS 1-4 AND 23-25 - 5-FU 400MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV FOLLOWED BY ONE MONTH BREAK AND ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV FOLLOWED BY ONE MONTH BREAK AND ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV. | MEDICAL ONCOLOGY | 26700 | 26700 | 26700 | 26700 | 26700 | 26700 | 26700 | 26700 |
224 | CMU0109 -iii-b : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACIL + LEUCOVORIN (II) ; DAYS 1, 2, 15, AND 16 - LEUCOVORIN 200MG/M2 IV, 5-FU 400MG/M2 IV PUSH AND 5-FU 600MG/M2 INFUSION | MEDICAL ONCOLOGY | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 |
225 | CMU0109 -iii-c : ESOPHAGEAL CANCER - POST-OPERATIVE - CAPECITABINE (I) ; DAYS 1-14 - CAPECITABINE 750-1000MG/M2 ORALLY TWICE DAILY; ; REPEAT EVERY 28 DAYS; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION | MEDICAL ONCOLOGY | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 |
226 | CMU0109 -iii-d : ESOPHAGEAL CANCER - POST-OPERATIVE - CAPECITABINE (II) ; DAYS 1-5 OR DAYS 1-7 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY, ; ONCE WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 |
227 | CMU0109 -iii-e : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACILDAYS 1-5 OR DAYS 1-7 - 5-FU 200-250MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS DAILY, ; ONCE WEEKLY FOR 5 WEEKS.ONCE WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 |
228 | CMU0109 -i-j : ESOPHAGEAL CANCER - NEO ADJUVANT - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 |
229 | CMU0109 -iv : ESOPHAGEAL CANCER - DEFINITIVE | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
230 | CMU0109 -iv-a : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & CISPLATIN (I) ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV | MEDICAL ONCOLOGY | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 |
231 | CMU0109 -iv-b : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & CISPLATIN (II) ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 - 5-FU 800 MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS. ; CYCLED EVERY 21 DAYS FOR 2 CYCLES | MEDICAL ONCOLOGY | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 |
232 | CMU0109 -iv-c : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & OXALIPLATIN ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY CONTINUOUS IV INFUSION. | MEDICAL ONCOLOGY | 27100 | 27100 | 27100 | 27100 | 27100 | 27100 | 27100 | 27100 |
233 | CMU0109 -iv-d : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE WEEKLY FOR 5 WEEKS | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
234 | CMU0109 -iv-e : ESOPHAGEAL CANCER - DEFINITIVE - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS | MEDICAL ONCOLOGY | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 |
235 | CMU0109 -iv-f : ESOPHAGEAL CANCER - DEFINITIVE - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV AND CARBOPLATIN 2MG/MIN/ML IV ; REPEAT WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
236 | CMU0109 -iv-g : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH DOCETAXEL (I) ; DAYS 1 AND 22 - DOCETAXEL 60MG/M2 IV ; DAYS 1 AND 22 - CISPLATIN 60-80MG/M2 IV GIVEN FOR 1 CYCLE | MEDICAL ONCOLOGY | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 |
237 | CMU0109 -iv-h : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH DOCETAXEL (II) ; DAY 1 - DOCETAXEL 20-30MG/M2 IV ; DAY 1 - CISPLATIN 20-30MG/M2 IV ; REPEAT WEEKLY FOR 5 WEEKS | MEDICAL ONCOLOGY | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 |
238 | CMU0109 -iv-i : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH PACLITAXEL ; DAYS 1, 8, 15, AND 22 - PACLITAXEL 60MG/M2 IV ; DAY 1 - CISPLATIN 75MG/M2 IV GIVEN FOR 1 CYCLE. | MEDICAL ONCOLOGY | 13800 | 13800 | 13800 | 13800 | 13800 | 13800 | 13800 | 13800 |
239 | CMU0109 -iv-j : ESOPHAGEAL CANCER - DEFINITIVE - IRINOTECAN & CISPLATIN ; DAYS 1, 8, 22, AND 29 - IRINOTECAN 65MG/M2 IV ; DAYS 1, 8, 22, AND 29 - CISPLATIN 30MG/M2 IV. | MEDICAL ONCOLOGY | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 |
240 | CMU0109 -iv-k : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45MG/M2 IV ; DAYS 1-5 - 5-FU 300MG/M2/DAY IV ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
241 | CMU0109 -iv-l : ESOPHAGEAL CANCER - DEFINITIVE - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 PO TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 |
242 | CMU0109 -v : ESOPHAGEAL CANCER - CONCURRENT CISPLATIN; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 5 CYCLES | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
243 | CMU0110 : GASTRIC CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
244 | CMU0110 -i : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
245 | CMU0110 -i-a : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV, CARBOPLATIN AUC 2MG/MIN/ML IV. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
246 | CMU0110 -i-b : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & CISPLATIN (I) ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1000MG/M2/DAY IV | MEDICAL ONCOLOGY | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 | 12600 |
247 | CMU0110 -i-c : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & CISPLATIN (II) ; DAYS 1-5 - CISPLATIN 15MG/M2 IV ONCE DAILY, 5-FU 800MG/M2/DAY IV ; REPEAT CYCLE EVERY 21 DAYS FOR 2 CYCLES. | MEDICAL ONCOLOGY | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 |
248 | CMU0110 -i-d : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & OXALIPLATIN (I)DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY IV. | MEDICAL ONCOLOGY | 27100 | 27100 | 27100 | 27100 | 27100 | 27100 | 27100 | 27100 |
249 | CMU0110 -i-e : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & OXALIPLATIN (II)DAY 1 - OXALIPLATIN 85MG/M2 AND LEUCOVORIN 400MG/M2 FOLLOWED BY 5-FU 400MG/M2 BOLUS, THEN 800MG/M2 24-HOUR CONTINUOUS INFUSION OVER DAYS 1 AND 2; THE FIRST 3 CYCLES WERE DELIVERED DURING RADIOTHERAPY (RT), THE OTHER 3 AFTER RT; 6 BIMONTHLY (14 DAYS) CYCLES. | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
250 | CMU0110 -i-f : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
251 | CMU0110 -i-g : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS | MEDICAL ONCOLOGY | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 |
252 | CMU0110 -i-h : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45-50MG/M2 IV WEEKLY ; DAYS 1-5 - 5-FU 300MG/M2 IV ; REPEAT CYCLE WEEKLY FOR 5 WEEKS | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
253 | CMU0110 -ii : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
254 | CMU0110 -i-i : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 |
255 | CMU0110 -ii-a : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - ECF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV, CISPLATIN 60MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2/DAY IV ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY | MEDICAL ONCOLOGY | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 |
256 | CMU0110 -ii-b : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - EOF (EPIRUBICIN/ OXALIPLATIN /FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. | MEDICAL ONCOLOGY | 19300 | 19300 | 19300 | 19300 | 19300 | 19300 | 19300 | 19300 |
257 | CMU0110 -ii-c : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - EPIRUBICIN + CISPLATIN + CAPECITABINE ; DAY 1 - EPIRUBICIN 50MG/M2 IV + CISPLATIN 60MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. | MEDICAL ONCOLOGY | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 |
258 | CMU0110 -ii-d : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - ECF MODIFICATION (EPIRUBICIN + OXALIPLATIN + CAPECITABINE) ; DAY 1 - EPIRUBICIN 50MG/M2 IV + OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELYREPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY | MEDICAL ONCOLOGY | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 |
259 | CMU0110 -ii-e : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL & CISPLATIN ; DAY 1 - CISPLATIN 75-80MG/M2 IV ; DAYS 1-5 - 5-FU 800MG/M2 IV ; REPEAT CYCLE EVERY 28 DAYS FOR 2-3 CYCLES PREOPERATIVELY AND 3-4 CYCLES POSTOPERATIVELY FOR A TOTAL OF 6 CYCLES. | MEDICAL ONCOLOGY | 7300 | 7300 | 7300 | 7300 | 7300 | 7300 | 7300 | 7300 |
260 | CMU0110 -iii : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
261 | CMU0110 -iii-a : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL + LEUCOVORIN (I) ; CYCLES 1, 3, AND 4 (BEFORE AND AFTER RADIATION) DAYS 1-5 - LEUCOVORIN 20MG/M2 IV, 5-FU 425MG/M2/DAY IV ; REPEAT CYCLE EVERY 28 DAYS. ; CYCLE 2 (WITH RADIATION) DAYS 1-4 AND 31-33 - LEUCOVORIN 20MG/M2 IVP ; DAYS 1-4 - 5-FU 400MG/M2/DAY IVP. ; REPEAT CYCLE EVERY 35 DAYS | MEDICAL ONCOLOGY | 26700 | 26700 | 26700 | 26700 | 26700 | 26700 | 26700 | 26700 |
262 | CMU0110 -iii-b : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL + LEUCOVORIN (II) ; DAYS 1, 2, 15, AND 16 - LEUCOVORIN 400MG/M2 IV, 5-FU 400MG/M2 IV AND 5-FU 1200MG/M2 INFUSION; ; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION. ; REPEAT CYCLE EVERY 28 DAYSREPEAT CYCLE EVERY 28 DAYS | MEDICAL ONCOLOGY | 15700 | 15700 | 15700 | 15700 | 15700 | 15700 | 15700 | 15700 |
263 | CMU0110 -iii-c : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CAPECITABINE (I) ; DAYS 1-14 - CAPECITABINE 750-1000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 28 DAYS; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION. | MEDICAL ONCOLOGY | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 |
264 | CMU0110 -iii-d : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CAPECITABINE (II) ; DAYS 1-5 OR DAYS 1-7 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY; WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 |
265 | CMU0110 -iii-e : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL ; DAYS 1-5 OR DAYS 1-7 - 5-FU 200-250MG/M2 IV; ; WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 |
266 | CMU0110 -iii-f : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 60MG/M2 IV. ; DAYS 1-14 - CAPECITABINE 1000MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE EVERY 21 DAYS FOR 6 CYCLES. | MEDICAL ONCOLOGY | 4200 | 4200 | 4200 | 4200 | 4200 | 4200 | 4200 | 4200 |
267 | CMU0110 -iii-h : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - OXALIPLATIN + CAPECITABINE ; DAY 1 - OXALIPLATIN 130MG/M2 IV. ; DAYS 1-14 - CAPECITABINE 1000MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE EVERY 21 DAYS FOR 8 CYCLES.REPEAT CYCLE EVERY 21 DAYS FOR 8 CYCLES. | MEDICAL ONCOLOGY | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 |
268 | CMU0111 : COLORECTAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
269 | CMU0111 -i : COLORECTAL CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
270 | CMU0111 -i-a : COLORECTAL CARCINOMA - FOLFOX (STAGE - III) - (OXALIPLATIN, LEUCOVORIN, 5-FU) ; DAY 1 - OXALIPLATIN 85MG/M2 IV, LEUCOVORIN 400MG/M2 IV, 5-FU 400MG/M2 IV, FOLLOWED BY 5-FU 1, 200MG/M2/DAY IV X 2 DAYS (TOTAL 2, 400MG/M2) OVER 46-48-HOUR CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS- UPTO 12 CYCLES | MEDICAL ONCOLOGY | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 |
271 | CMU0111 -i-b : COLORECTAL CARCINOMA - CAPEOX (STAGE - III) (OXALIPLATIN, CAPECITABINE) ; DAY 1 - OXALIPLATIN 130MG/M2 IV OVER 2 HOURS ; DAYS 1-14 - CAPECITABINE 1, 000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 MONTHS | MEDICAL ONCOLOGY | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 |
272 | CMU0111 -i-c : COLORECTAL CARCINOMA - FLOX (STAGE - III) (5-FU, LEUCOVORIN, OXALIPLATIN) ; 5-FU 500MG/M2 IV BOLUS WEEKLY X 6, LEUCOVORIN 500MG/M2 IV WEEKLY X 6, EACH ; OXALIPLATIN 85MG/M2 IV ON WEEKS 1, 3, AND 5 ; 8-WEEK CYCLE X 3 CYCLES ; | MEDICAL ONCOLOGY | 31500 | 31500 | 31500 | 31500 | 31500 | 31500 | 31500 | 31500 |
273 | CMU0111 -i-d : COLORECTAL CARCINOMA - CAPECITABINE ; CAPECITABINE 1, 250MG/M2 - BD / TDS D 1-14 ; EVERY 3 WEEKS * 24 WEEKSL CARCINOMA - CAPECITABINE ; CAPECITABINE 1, 250MG/M2 - BD / TDS D 1-14 ; EVERY 3 WEEKS * 24 WEEKS | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
274 | CMU0111 -i-e : COLORECTAL CARCINOMA - FLUOROURACIL + LEUCOVORIN (I) ; LEUCOVORIN 500MG/M2 WEEKLY X 6 WEEKS, ; 5-FU 500MG/M2 WEEKLY X 6 WEEKS. ; REPEAT CYCLE EVERY 8 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 24900 | 24900 | 24900 | 24900 | 24900 | 24900 | 24900 | 24900 |
275 | CMU0111 -i-f : COLORECTAL CARCINOMA - FLUOROURACIL + LEUCOVORIN (II)SIMPLIFIED BIWEEKLY INFUSION. ; LEUCOVORIN 400MG/M2 IV, 5-FU BOLUS 400MG/M2 AND THEN 1, 200MG/M2/DAY X 2 DAYS (TOTAL 2, 400MG/M2 OVER 46-48 HOURS) ; REPEAT CYCLE EVERY 2 WEEKS FOR 6 CYCLES. | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
276 | CMU0111 -ii : COLORECTAL CARCINOMA - CONCURRENT | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
277 | CMU0111 -ii-a : COLORECTAL CARCINOMA - CONCURRENT - 5FU - WITH XRT ; DAYS 1-5 OR 1-7 - 5-FU 225MG/M2 IV ; WITH EXTERNAL BEAM RADIOTHERAPY | MEDICAL ONCOLOGY | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 |
278 | CMU0111 -ii-b : COLORECTAL CARCINOMA - CONCURRENT - FLUOROURACIL + LEUCOVORIN - WITH XRT ; DAYS 1-4 - 5-FU 400MG/M2 IV + LEUCOVORIN 20MG/M2 IV. ; REPEAT CYCLE DURING WEEKS 1 AND 5 OF XRT. | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
279 | CMU0111 -ii-c : COLORECTAL CARCINOMA - CONCURRENT - CAPECITABINE - WITH XRT ; CAPECITABINE TABLET 825MG / M2 TWICE DAILY ON DAYS 1-5 ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. | MEDICAL ONCOLOGY | 1400 | 1400 | 1400 | 1400 | 1400 | 1400 | 1400 | 1400 |
280 | CMU0112 : OSTEOSARCOMA/ BONE TUMORS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
281 | CMU0112 -i-a : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - CISPLATIN + DOXORUBICIN ; DAYS 1-3 - DOXORUBICIN 25MG/M2/DAY IV, ; DAY 1 - CISPLATIN 100MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES | MEDICAL ONCOLOGY | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 |
282 | CMU0112 -i-b-1 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - PRE OPERATIVE ; DAYS 1 AND 28 - METHOTREXATE 8G/M2 IV ; DAYS 7-9 AND 34-36 - CISPLATIN 120MG/M2 BY INFUSION FOR 72 HOURS. ; DAYS 9 AND 36 - DOXORUBICIN 60MG/M2 IV | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
283 | CMU0112 -i-b-2 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - POST OPERATIVE NECROSIS < 90% ; DAYS 1, 48, 96, AND 144 - DOXORUBICIN 45MG/M2/DAY FOR 2 CONSECUTIVE DAYS ; DAYS 21, 69, AND 117 - METHOTREXATE 8G/M2 IV ; DAYS 27, 75, AND 123 - CISPLATIN 120MG/M2 BY INFUSION FOR 72 HOURS. | MEDICAL ONCOLOGY | 42000 | 42000 | 42000 | 42000 | 42000 | 42000 | 42000 | 42000 |
284 | CMU0112 -i-b-3 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - POST OPERATIVE NECROSIS > 90%POSTOPERATIVE CHEMOTHERAPY (NECROSIS | MEDICAL ONCOLOGY | 62000 | 62000 | 62000 | 62000 | 62000 | 62000 | 62000 | 62000 |
285 | CMU0112 -i-c : DOXORUBICIN + CISPLATIN + IFOSFAMIDE + HIGH-DOSE METHOTREXATE (INCLUDING SURGERY COST) | MEDICAL ONCOLOGY | 117100 | 117100 | 117100 | 117100 | 117100 | 117100 | 117100 | 117100 |
286 | CMU0112 -i-d : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - IFOSFAMIDE + CISPLATIN + EPIRUBICIN ; DAY 1 - EPIRUBICIN 90MG/M2 IV, CISPLATIN 100MG/M2 IV ; DAYS 2-4 - IFOSFAMIDE 2.0G/M2 WITH MESNA ; REPEAT CYCLE EVERY 21 DAYS. (3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY). | MEDICAL ONCOLOGY | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 |
287 | CMU0112 -ii : OTHER BONE TUMORS - CHORDROMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
288 | CMU0112 -ii-a : OTHER BONE TUMORS - CHORDROMA - IMATINIB ; IMATINIB 800 MG ONCE DAILY | MEDICAL ONCOLOGY | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 |
289 | CMU0112 -ii-b : OTHER BONE TUMORS - CHORDROMA - IMATINIB + CISPLATIN ; IMATINIB 400MG OD + CISPLATIN 25MG/M2 WEEKLY. | MEDICAL ONCOLOGY | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 |
290 | CMU0112 -ii-c : OTHER BONE TUMORS - CHORDROMA - IMATINIB + SIROLIMUS ; IMATINIB 400MG OD + SIROLIMUS 2MG OD | MEDICAL ONCOLOGY | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 |
291 | CMU0112 -ii-d : OTHER BONE TUMORS - CHORDROMA - ERLOTINIB ; ERLOTINIB 150MG OD | MEDICAL ONCOLOGY | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 |
292 | CMU0112 -ii-e : OTHER BONE TUMORS - CHORDROMA - SUNITINIB ; SUNITINIB 37.5MG OD | MEDICAL ONCOLOGY | 29900 | 29900 | 29900 | 29900 | 29900 | 29900 | 29900 | 29900 |
293 | CMU0112 -iii : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
294 | CMU0112 -iii-a : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - DENOSUMAB ; DENOSUMAB 120MG SUBCUTANEOUS ON WEEK 1, 2 AND 3 OF A 4 WEEK CYCLE | MEDICAL ONCOLOGY | 58800 | 58800 | 58800 | 58800 | 58800 | 58800 | 58800 | 58800 |
295 | CMU0112 -iii-b : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - INTERFERON ALFA ; INTERFERON ALFA- 2A THRICE WEEKLY | MEDICAL ONCOLOGY | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 |
296 | CMU0112 -iii-c : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - PEGINTERFERON ; PEGINTERFERON ALFA-2A 1.0MCG/KG SQ INJECTION WEEKLY. | MEDICAL ONCOLOGY | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 |
297 | CMU0112 -iv : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
298 | CMU0112 -iv-a : VAC AND IE CYCLES | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
299 | CMU0112 -iv-b : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA VAIA ; DAY 1 - VINCRISTINE 1.5MG/M2 IV ; DAYS 1-3 - IFOSFAMIDE 2, 000MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS. | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
300 | CMU0112 -vi : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA VIDE (VINCRISTINE + IFOSFAMIDE + DOXORUBICIN + ETOPOSIDE) ; DAY 1 - VINCRISTINE 1.4MG/M2 (MAX 2MG), ; DAYS 1-3 - DOXORUBICIN 20MG/M2 IV + IFOSFAMIDE 3MG/M2 IV + MESNA 3G/M2 + ETOPOSIDE 150MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES. | MEDICAL ONCOLOGY | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 |
301 | CMU0113 : WILMS TUMOR | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
302 | CMU0113 -a : WILMS TUMOR - VINCRISTINE & ACTINOMYCIN D ; DACTINOMYCIN 45MCG/KG - WEEK - 0, 3, 6, 9, 12, 15, 18 ; VINCRISTINE 1.5 MG/M2 - WEEK - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18 | MEDICAL ONCOLOGY | 20400 | 20400 | 20400 | 20400 | 20400 | 20400 | 20400 | 20400 |
303 | CMU0113 -b : WILMS TUMOR - DACTINOMYCIN, VINCRISTINE & ADRIAMYCIN ; DACTINOMYCIN 1.35 MG /M2 - WEEK - 0, 6, 12, 18, 24 ; ADRIYAMYCIN 30-45 MG /M2- WEEK - 3, 9, 15, 21 ; VINCRISTINE 2MG MAX- WEEK - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 21, 24 | MEDICAL ONCOLOGY | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 |
304 | CMU0113 -c : WILMS TUMOR - ADRIAMYCIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, VINCRISTINE ; CYCLOPHOSPHAMIDE 440MG/M2/DAY - WEEK 3, 9, 15, 21 FOR 5 DAYS, WEEK - 6, 12, 18, 24 FOR 3 DAYS ; ADRIYAMYCIN 30-45MG /M2- WEEK -0, 6, 12, 18, 24 ; VINCRISTINE 2MG (MAX)- WEEK - 1, 2, 4, 5, 6, 7, 8, 10, 11, 12, 13, 18, 24 ; ETOPOSIDE 100MG /M2- WEEK - 3, 9, 15, 21 | MEDICAL ONCOLOGY | 56400 | 56400 | 56400 | 56400 | 56400 | 56400 | 56400 | 56400 |
305 | CMU0113 -d : WILMS TUMOR - CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN ; CYCLOPHOSPHAMIDE 440MG/M2/DAY - WEEK 6, 15, 24 *5 DAYS / WEEK ; CARBOPLATIN 500MG/M2 - WEEK - 0, 3, 9, 12, 18, 21 *2 DAYS / WEEK ; ETOPOSIDE 100MG/M2 - WEEK - 0, 3, 9, 12, 18, 21 *5 DAYS / WEEK | MEDICAL ONCOLOGY | 88700 | 88700 | 88700 | 88700 | 88700 | 88700 | 88700 | 88700 |
306 | CMU0114 : HEPATOBLASTOMA- OPERABLEHEPATOBLASTOMA- OPERABLE | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
307 | CMU0114 -a : HEPATOBLASTOMA- OPERABLE - PLADO - CISPLATIN + DOXORUBICIN ; CISPLATIN (PLA) (80MG/M2 / IV), DOXORUBICIN (DO) (30 MG/M2 IV ; EVERY 21 DAYS FOR 6 CYCLES | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
308 | CMU0114 -b : HEPATOBLASTOMA- OPERABLE - CISPLATIN + VINCRISTINE +5FU ; CISPLATIN (90 MG/M2), VINCRISTINE (1.5MG/M2), 5-FU(5-FLUROURACIL- 600 MG/M2) ; EVERY 21 DAYS FOR 6 CYCLES | MEDICAL ONCOLOGY | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 |
309 | CMU0115 : HEPATOCELLULAR CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
310 | CMU0115 -a : HEPATOCELLULAR CARCINOMA - SORAFENIB ; SORAFENIB 400 MG PO BID | MEDICAL ONCOLOGY | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 |
311 | CMU0116 : NEUROBLASTOMA ALL STAGES | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
312 | CMU0116 A : NEUROBLASTOMA ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN | MEDICAL ONCOLOGY | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 |
313 | CMU0116 B : NEUROBLASTOMA ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300MG/M2 ; ADRIAMYCIN 60MG/M2 ; VINCRISTINE 1.5MG/M2 | MEDICAL ONCOLOGY | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 |
314 | CMU0116 C : NEUROBLASTOMA ALL STAGES - CISPLATIN & ETOPOSIDE ; DAYS 1-5 - CISPLATIN - 20MG/M2 ; DAYS 1-5 - ETOPOSIDE - 70 MG/M2 | MEDICAL ONCOLOGY | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 |
315 | CMU0116 D : NEUROBLASTOMA ALL STAGES - CARBOPLATIN & ETOPOSIDE ; DAYS 1-2 - CARBOPLATIN - 500MG/M2 ; DAYS 1-5 - ETOPOSIDE 100MG/M2 | MEDICAL ONCOLOGY | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 |
316 | CMU0116 E : NEUROBLASTOMA ALL STAGES - FOR STAGE IV PALLIATIVE CHEMOTHERAPY ONLY | MEDICAL ONCOLOGY | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 |
317 | CMU0117 : RETINOBLASTOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
318 | CMU0117 -a : RETINOBLASTOMA - MELPHALAN - INTRA-ARTERIAL ; MELPHALAN - 3-7.5MG - INTRA-ARTERIAL | MEDICAL ONCOLOGY | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 |
319 | CMU0117 -b : RETINOBLASTOMA - CARBOPLATIN - INTRA-ARTERIAL ; CARBOPLATIN 15-30 MG - INTRA-ARTERIAL | MEDICAL ONCOLOGY | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 |
320 | CMU0117 -c : RETINOBLASTOMA - TOPOTECAN - INTRA-ARTERIAL ; TOPOTECAN 0.15-1.5 MG - INTRA-ARTERIAL | MEDICAL ONCOLOGY | 10400 | 10400 | 10400 | 10400 | 10400 | 10400 | 10400 | 10400 |
321 | CMU0117 -d : RETINOBLASTOMA - METHOTREXATE - INTRA-ARTERIAL ; METHOTREXATE 6-12 MG - INTRA-ARTERIAL | MEDICAL ONCOLOGY | 9100 | 9100 | 9100 | 9100 | 9100 | 9100 | 9100 | 9100 |
322 | CMU0117 -e : RETINOBLASTOMA - CARBOPLATIN - PERI OCULAR ; CARBOPLATIN 20MG/M2 - PERI OCULAR | MEDICAL ONCOLOGY | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 |
323 | CMU0117 -f : RETINOBLASTOMA - TOPOTECAN - PERI OCULAR ; TOPOTECAN 0.09 - 0.27 - PERI OCULAR | MEDICAL ONCOLOGY | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 |
324 | CMU0117 -g : RETINOBLASTOMA - MELPHALAN - INTRA-VITREAL ; MELPHALAN 20-30 MCG / 0.1CC - INTRA-VITREAL | MEDICAL ONCOLOGY | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 |
325 | CMU0117 -h : RETINOBLASTOMA - CARBOPLATIN - INTRA-VITREAL ; CARBOPLATIN 3-6MCG / 0.05CC - INTRA-VITREAL | MEDICAL ONCOLOGY | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 |
326 | CMU0117 -i : RETINOBLASTOMA - METHOTREXATE - INTRA-VITREAL ; METHOTREXATE 400MCG/0.1CC - INTRA-VITREAL | MEDICAL ONCOLOGY | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 |
327 | CMU0117 -j : RETINOBLASTOMA - CARBOPLATIN + ETOPOSIDE + VINCRISTINE ; CARBOPLATIN 560MG/M2 ; ETOPOSIDE 150MG/M2 ; VINCRISTINE 1.5MG/M2 | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
328 | CMU0118 : HISTIOCYTOSIS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
329 | CMU0118 -a : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - 1; PREDNISOLONE AND VINBLASTINE - 1 ; PREDNISOLONE - 6 WEEKS ORAL ; VINBLASTINE 1, 2, 3, 4, 5, 6 | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
330 | CMU0118 -b : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - 2; PREDNISOLONE AND VINBLASTINE - 1 ; PREDNISOLONE - 6 WEEKS ORAL ; VINBLASTINE 1, 2, 3, 4, 5, 6 | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
331 | CMU0118 -c : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - CONTINUATION; PREDNISOLONE AND VINBLASTINE - CONTINUATION AFTER EITHER COURSE 1 OR BOTH 1 & 2 ; PREDNISOLONE - 5 DAYS A WEEK ORAL ; VINBLASTINE -IV ; REPEAT EVERY 3 WEEKS TILL 1 YEAR | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
332 | CMU0119 : RHABDOMYOSARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
333 | CMU0119 -a : RHABDOMYOSARCOMA - VAC (VINCRISTINE + DACTINOMYCIN + CYCLOPHOSPHAMIDE + MESNA ) ; DAY -1 - VINCRISTINE 1.5 MG /M2 IV (2 MG MAX), DOXORUBICIN 75 MG /M2 IV, CYCLOPHOSPHAMIDE 1200 MG /M2 IV + MESNA ; REPEAT AT 21 DAY INTERVALS FOR 4-6 CYCLES | MEDICAL ONCOLOGY | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 |
334 | CMU0119 -b : RHABDOMYOSARCOMA - IVA (VINCRISTINE + DACTINOMYCIN + IFOSFAMIDE + MESNA ) ; DAY 1, 2 - IFOSFAMIDE IV 3 G/M2 + MESNA ; DAY 1 - VINCRISTINE IV 1.5 MG/M2 (MAX 2 MG), ACTINOMYCIN-D IV 1.5 MG/M2 (MAX 2 MG) ; REPEAT AT 21 DAY INTERVALS FOR 6 CYCLES | MEDICAL ONCOLOGY | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 |
335 | CMU0119 -c : RHABDOMYOSARCOMA - IVAD (VINCRISTINE + DOXORUBICIN + IFOSFAMIDE + MESNA ) ; DAYS 1 AND 2 - IFOSFAMIDE 3 G/M2 + MESNA, DOXORUBICIN 30MG/M2 ; DAY 1 - VINCRISTINE 1.5 MG/M2, ACTINOMYCIN-D 1.5 MG/M2 ; REPEAT AT 21 DAY INTERVALS FOR 6 CYCLES | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
336 | CMU0120 : EWINGS SARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
337 | CMU0120 -i : EWINGS SARCOMA - INDUCTION TREATMENT I | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
338 | CMU0120 -i-a : EWINGS SARCOMA - INDUCTION TREATMENT - VIDE ; DAY 1 - VINCRISTINE 1.5MG/M2(MAX 2MG) IV ; DAYS 1-3 - DOXORUBICIN 20MG/M2 IV, IFOSFAMIDE 3G/M2IV, MESNA CONTINUOUS IV, ETOPOSIDE 150MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES | MEDICAL ONCOLOGY | 8800 | 8800 | 8800 | 8800 | 8800 | 8800 | 8800 | 8800 |
339 | CMU0120 -i-b : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE ; | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
340 | CMU0120 -i-b-1 : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE - VAC ; DAY 1 - VINCRISTINE 2MG/M2 (MAX 2MG) IV, DOXORUBICIN 75MG/M2 IV BOLUS, CYCLOPHOSPHAMIDE 1, 200MG/M2 IV, MESNA. ; DACTINOMYCIN 1.25MG/M2 IV CAN BE SUBSTITUTED FOR DOXORUBICIN WHEN A TOTAL DOXORUBICIN DOSE OF 375MG/M2 IS REACHED. | MEDICAL ONCOLOGY | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 |
341 | CMU0120 -i-b-2 : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE - IE ; IE CYCLES ; DAYS 1-5 - IFOSFAMIDE 1, 800MG/M2 IV + MESNA + ETOPOSIDE 100MG/M2 IV. ; REPEAT EACH CYCLE EVERY 3 WEEKS FOR 17 CYCLES. | MEDICAL ONCOLOGY | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 |
342 | CMU0120 -i-c : EWINGS SARCOMA - INDUCTION TREATMENT - VAIA - 4 DAY REGIMEN ; DAY 1 - VINCRISTINE 1.5MG/M2IV ; DAYS 1-3 - IFOSFAMIDE 2, 000MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, THEN LOCAL THERAPY, FOLLOWED BY 10 ADDITIONAL CYCLES OF VAIA FOR HIGH RISK AND ; 10 ADDITIONAL CYCLES OF VAIA OR 10 CYCLES OF VACA FOR STANDARD-RISK PATIENTS | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
343 | CMU0120 -i-d : EWINGS SARCOMA - INDUCTION TREATMENT - VAIA - 24 DAY REGIMEN ; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.5MG/M2 IV ; DAYS 1, 2, 22, 23, 43, AND 44 - IFOSFAMIDE 3, 000MG/M2 IV + MESNA ; DAYS 1, 2, 43, AND 44 - DOXORUBICIN 30MG/M2 IV ; DAYS 22, 23, AND 24 - DACTINOMYCIN 0.5MG/M2 IV ; AFTER COMPLETION OF ONE 9-WEEK CYCLE, LOCAL THERAPY FOLLOWED BY 3 ADDITIONAL CYCLES. | MEDICAL ONCOLOGY | 18600 | 18600 | 18600 | 18600 | 18600 | 18600 | 18600 | 18600 |
344 | CMU0120 -i-e : EWINGS SARCOMA - INDUCTION TREATMENT - VACA ; DAY 1 - VINCRISTINE 1.5MG/M2 IV + CYCLOPHOSPHAMIDE 1, 200MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 10 CYCLES. | MEDICAL ONCOLOGY | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 |
345 | CMU0120 -ii : EWINGS SARCOMA - MAINTENANCE TREATMENT | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
346 | CMU0120 -ii-a : EWINGS SARCOMA - MAINTENANCE TREATMENT - ETOPOSIDE/IFOSFAMIDE ; DAYS 1-5 - IFOSFAMIDE 1, 800MG/M2/DAY IV + MESNA ; DAYS 1-5 - ETOPOSIDE 100MG/M2/DAY IV. | MEDICAL ONCOLOGY | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 |
347 | CMU0121 : PALLIATIVE CHEMOTHERAPY (ANY REGIMEN)- MAXIMUM PAYABLE | MEDICAL ONCOLOGY | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 |
348 | CMU0122 : CERVICAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
349 | CMU0122 -a : CERVICAL CANCER - CISPLATIN ; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 6 CYCLES | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
350 | CMU0122 -b : CERVICAL CANCER - CISPLATIN & 5FU WITH RT ; DAYS 1-5 OF RADIOTHERAPY - CISPLATIN 75MG/M2 IV, 5-FU 4, 000MG/M2 IV OVER 96 HOURS ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 | MEDICAL ONCOLOGY | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 |
351 | CMU0122 -c : CERVICAL CANCER - CISPLATIN & 5FU ; DAYS 1 AND 29 - CISPLATIN 50MG/M2 IV ; DAYS 2-5, AND 30-33 - 5-FU 1, 000MG/M2 IV | MEDICAL ONCOLOGY | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 |
352 | CMU0123 : VULVAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
353 | CMU0123 -a : VULVAL CANCER - CISPLATIN ; DAY 1 - 40 MG/M 2 IV | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
354 | CMU0123 -b : VULVAL CANCER - CISPLATIN + 5FU ; DAYS 1-5 OF RADIOTHERAPY - CISPLATIN 75MG/M2 IV, 5-FU 4, 000MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS - TOTAL 3 CYCLES | MEDICAL ONCOLOGY | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 |
355 | CMU0123 -c : VULVAL CANCER - 5-FU + MITOMYCIN ; 5-FU + MITOMYCIN ; DAYS 1-4 AND 29-32 - 5-FU 1, 000MG/M2/DAY CONTINUOUS IV INFUSION ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS (MAXIMUM 20MG PER COURSE), | MEDICAL ONCOLOGY | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 |
356 | CMU0123 -e : VULVAL CANCER - CISPLATIN + 5FU ; DAYS 1 AND 29 - CISPLATIN 50MG/M2 IV ; DAYS 2-5, AND 30-33 - 5-FU 1, 000MG/M2 IV | MEDICAL ONCOLOGY | 11700 | 11700 | 11700 | 11700 | 11700 | 11700 | 11700 | 11700 |
357 | CMU0124 : VAGINAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
358 | CMU0124 -a : VAGINAL CANCER - CISPLATIN ; CISPLATIN 75MG/M2 ; ONCE WEEKLY FOR UP TO 6 DOSES | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
359 | CMU0125 : OVARIAN CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
360 | CMU0125 -a : OVARIAN CANCER - PACLITAXEL + CISPLATIN ; DAY 1 - PACLITAXEL 135MG/M2 CONTINUOUS IV ; DAY 2 - CISPLATIN 75-100MG/M2 ; DAY 8 - PACLITAXEL 60MG/M2 ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES. | MEDICAL ONCOLOGY | 9300 | 9300 | 9300 | 9300 | 9300 | 9300 | 9300 | 9300 |
361 | CMU0125 -b : OVARIAN CANCER - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 175MG/M2 IV, CARBOPLATIN AUC 5-6 MG/MIN/ML IV ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES | MEDICAL ONCOLOGY | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 |
362 | CMU0125 -c : OVARIAN CANCER - DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 60-75MG/M2 IV, CARBOPLATIN AUC 5-6 MG/MIN/ML ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES | MEDICAL ONCOLOGY | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 |
363 | CMU0126 : ENDOMETRIAL CANCER (PALLIATIVE CHEMOTHERAPY ONLY) | MEDICAL ONCOLOGY | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 |
364 | CMU0127 : OVARY- GERM CELL TUMOR | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
365 | CMU0127 -a : OVARY- GERM CELL TUMOR - BEP (BLEOMYCIN + ETOPOSIDE + CISPLATIN) ; DAYS 1, 8, 15 - BLEOMYCIN 30 UNITS/WK IV, ETOPOSIDE 100 MG/M 2/DAY IV ; DAYS 1-5 - CISPLATIN 20 MG/M 2/DAY IV ; REPEAT EVERY 21 DAYS 3-4 CYCLES | MEDICAL ONCOLOGY | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 |
366 | CMU0127 -b : OVARY- GERM CELL TUMOR - EP ( ETOPOSIDE + CARBOPLATIN) ; DAY 1 - CARBOPLATIN 400 MG/M 2 IV ON DAYS 1-3 ; REPEAT EVERY 28 DAYS FOR THREE CYCLES | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
367 | CMU0128 : GESTATIONAL TROPHOBLAST DISEASES | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
368 | CMU0128 -a : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE (5 DAYS REGIMEN) ; DAYS 1-5 - MTX 0.4 MG/KG/DAY IV OR IM FOR 5 DAYS, NOT TO EXCEED 25 MG/DAY ; REPEAT CYCLE EVERY 14 DAYS | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
369 | CMU0128 -b : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE (8-DAY ALTERNATING REGIMEN) ; DAYS 1, 3, 5, AND 7 - MTX 1 MG/KG IM, ; DAYS 2, 4, 6, AND 8 - FOLINIC ACID 15 MG ; REPEAT CYCLE EVERY 14 DAYS | MEDICAL ONCOLOGY | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 |
370 | CMU0128 -c : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE + FOLINIC ACID ; DAY 1 - MTX 100 MG/M 2 IVP, THEN 200 MG/M 2 INFUSION ; DAY 2 - FOLINIC ACID 15 MG IM/PO Q12H FOR 4 DOSES ; REPEAT CYCLE EVERY 18 DAYS | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
371 | CMU0128 -d : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE - WEEKLY ; MTX 30-50 MG/M 2 IM WEEKLY | MEDICAL ONCOLOGY | 1400 | 1400 | 1400 | 1400 | 1400 | 1400 | 1400 | 1400 |
372 | CMU0128 -e : GESTATIONAL TROPHOBLAST DISEASES - ACT-D ; ACT-D 10-13 MCG/KG OR 0.5-MG FLAT DOSE IV QD FOR 5D ; REPEAT CYCLE EVERY 14 DAYS | MEDICAL ONCOLOGY | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 |
373 | CMU0128 -f : GESTATIONAL TROPHOBLAST DISEASES - ACTINOMYCIN ; ACTINOMYCIN 1.25 MG/M 2 IV ; REPEAT EVERY 2 WEEKS | MEDICAL ONCOLOGY | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 |
374 | CMU0128 -g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (COMPLETE) ; DAY 1 - ACT-D - 0.5 MG IV, ETOPOSIDE - 100 MG/M2 IV, MTX - 300 MG/M2 IV ; DAY 2 - ACT-D - 0.5 MG IV, ETOPOSIDE - 100 MG/M2 IV, LEUCOVORIN - 15 MG PO/IM Q12H 4 DOSES ; DAY 8 - VINCRISTINE - 0.8 MG/M2 IV, CYCLOPHOSPHAMIDE - 600 MG/M2 IV ; REPEAT CYCLE EVERY 14 DAYS | MEDICAL ONCOLOGY | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 |
375 | CMU0129 : TESTICULAR CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
376 | CMU0129 -a : TESTICULAR CANCER - EP ; DAYS 1-5 - ETOPOSIDE 100MG/M2, CISPLATIN 20MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 |
377 | CMU0129 -b : TESTICULAR CANCER - BEP ; DAYS 1-5 - CISPLATIN 20MG/M2, ETOPOSIDE 100MG/M2 ; DAYS 1, 8, AND 15 OR DAYS 2, 9, OR 16 - BLEOMYCIN 30 UNITS IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES. | MEDICAL ONCOLOGY | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 |
378 | CMU0129 -c : TESTICULAR CANCER - VIP ; DAY 1 (BEFORE IFOSFAMIDE) - MESNA 120MG/M2 IV ; DAYS 1-5 - ETOPOSIDE 75MG/M2 IV, MESNA 1, 200MG/M2 IV, IFOSFAMIDE 1, 200MG/M2 IV + CISPLATIN 20MG/M2. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 |
379 | CMU0130 : PROSTATE CANCERPROSTATE CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
380 | CMU0130 -a : PROSTATE CANCER - DOCETAXEL + PREDNISONE ; DAY 1 - DOCETAXEL 75MG/M2 IV, PREDNISONE 5MG ORALLY TWICE DAILY. ; ONCE EVERY 3 WEEKS, REPEAT FOR UP TO 10 CYCLES IF TOLERATED | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
381 | CMU0130 -c : PROSTATE CANCER - ZOLEDRONIC ACID FOR SKELETAL METASTASIS | MEDICAL ONCOLOGY | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 |
382 | CMU0131 : FEBRILE NEUTROPENIA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
383 | CMU0131 -a : FEBRILE NEUTROPENIA - FIRST-LINE MONOTHERAPY ; PIPERACILLIN-TAZOBACTAM 4.5 G ; CEFEPIME 2 G ; MEROPENEM 1 G ; IMIPENEM-CILASTATIN 500 MG | MEDICAL ONCOLOGY | 14200 | 14200 | 14200 | 14200 | 14200 | 14200 | 14200 | 14200 |
384 | CMU0131 -b : FEBRILE NEUTROPENIA - SECOND-LINE DUAL THERAPY ; PIPERACILLIN-TAZOBACTAM 4.5 G IV PLUS AN AMINOGLYCOSIDE ; MEROPENEM 1 G IV PLUS AN AMINOGLYCOSIDE ; IMIPENEM-CILASTATIN 500 MG IV PLUS AN AMINOGLYCOSIDE | MEDICAL ONCOLOGY | 20500 | 20500 | 20500 | 20500 | 20500 | 20500 | 20500 | 20500 |
385 | CMU0132 : THYROID CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
386 | CMU0132 -a : THYROID CANCER - SORAFENIB ; SORAFENIB 400 MG PO BID | MEDICAL ONCOLOGY | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 |
387 | CMU0132 -b : THYROID CANCER - SUNITINIB ; SUNITINIB 50 MG | MEDICAL ONCOLOGY | 29900 | 29900 | 29900 | 29900 | 29900 | 29900 | 29900 | 29900 |
388 | CMU0132 -c : THYROID CANCER - PAZOPANIB | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
389 | CMU0132 -d : THYROID CANCER - DOXORUBICIN ; DOXORUBICIN 60 MG/M2 AS MONOTHERAPY OR IN COMBINATION WITH CISPLATIN 40 MG/M2 | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
390 | CMU0133 : THYMOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
391 | CMU0133 -a : THYMOMA - CAP ; DAY 1 - CISPLATIN 50MG/M2 IV, DOXORUBICIN 50MG/M2 IV, CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT EVERY 21 DAYS FOR A MAX OF 8 CYCLES. | MEDICAL ONCOLOGY | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 |
392 | CMU0133 -b : THYMOMA - CAPP ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV ; DAYS 1-3 - CISPLATIN 30MG/M2 IV ; DAYS 1-3 - DOXORUBICIN 20MG/M2 ; DAYS 1-5 - PREDNISONE 100MG. ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
393 | CMU0133 -c : THYMOMA - ADOC ; DAY 1 - CISPLATIN 50MG/M2 IV, DOXORUBICIN 40MG/M2 IV ; DAY 3 - VINCRISTINE 0.6MG/M2 IV ; DAY 4 - CYCLOPHOSPHAMIDE 700MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 5 CYCLES. | MEDICAL ONCOLOGY | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 |
394 | CMU0133 -d : THYMOMA - PE ; DAY 1 - CISPLATIN 60MG/M2 IV ; DAYS 1-3 - ETOPOSIDE 120MG/M2 IV ; REPEAT EVERY 3 WEEKS FOR A MAX OF 8 CYCLES. | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
395 | CMU0133 -e : THYMOMA - VIP ; DAYS 1-4 - ETOPOSIDE 75MG/M2 IV, IFOSFAMIDE 1.2G/M2 IV, CISPLATIN 20MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
396 | CMU0133 -f : THYMOMA - CARBOPLATIN+PACLITAXEL ; DAY 1 - PACLITAXEL 225MG/M2 IV, CARBOPLATIN AUC = 6 IV ; REPEAT EVERY 3 WEEKS FOR A MAX OF 6 CYCLES. | MEDICAL ONCOLOGY | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 |
397 | CMU0134 : BRAIN CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
398 | CMU0134 -i : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
399 | CMU0134 -i-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - COMBINATION PCV (LOMUSTINE + PROCARBAZINE + VINCRISTINE) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY. ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY. ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS. | MEDICAL ONCOLOGY | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 |
400 | CMU0134 -i-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE (7 WEEKS) ; DAYS 1-49 - TEMOZOLOMIDE 75MG/M2 ORALLY. ; REPEAT CYCLE EVERY 11 WEEKS (7 WEEKS ON/4 WEEKS OFF) FOR 6 CYCLES. | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
401 | CMU0134 -i-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE MONTHLY 5-DAY COURSE ; TEMOZOLOMIDE MONTHLY 5-DAY COURSES AT DOSES OF 180 - 200MG/M2/DAY | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
402 | CMU0134 -i-d : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE (3 WEEKS) ; DAYS 1-21 - TEMOZOLOMIDE 75MG/M2/DAY ORALLY. ; REPEAT CYCLE EVERY 28 DAYS. | MEDICAL ONCOLOGY | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 |
403 | CMU0134 -ii : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMASSYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
404 | CMU0134 -ii-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - TEMOZOLOMIDE MONTHLY 5-DAY COURSE ; DAYS 1-5 - TEMOZOLOMIDE 200MG/M2/DAY ORALLY. ; REPEAT CYCLE EVERY 4 WEEKS UNTIL DISEASE PROGRESSION OR FOR UP TO 24 CYCLES. | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
405 | CMU0134 -ii-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - PCV WITH DEFERRED RT (LOMUSTINE + PROCARBAZINE + VINCRISTINE) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS | MEDICAL ONCOLOGY | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 |
406 | CMU0134 -ii-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
407 | CMU0134 -ii-c-1 : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; DAILY ORAL TEMOZOLOMIDE (75MG/M2/DAY, 7 DAYS PER WEEK FROM THE FIRST TO THE LAST DAY OF RADIOTHERAPY) | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
408 | CMU0134 -ii-c-2 : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - ADJUVANT TEMOZOLOMIDE - PRECEEDED BY CONCURRENT TEMOZOLOMIDE (WITH RT) ; TEMOZOLOMIDE 150-200MG/M2/DAY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
409 | CMU0134 -ii-d : ADJUVANT TEMOZOLOMIDE | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
410 | CMU0134 -ii-e : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - PCV FOR 1P19Q CO-DELETED (WITH RADIOTHERAPY) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS. FOR 6 CYCLES | MEDICAL ONCOLOGY | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 |
411 | CMU0134 -iii : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
412 | CMU0134 -iii-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; DAILY ORAL TEMOZOLOMIDE (75MG/M2/DAY, 7 DAYS PER WEEK FROM THE FIRST TO THE LAST DAY OF RADIOTHERAPY) | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
413 | CMU0134 -iii-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - ADJUVANT TEMOZOLOMIDE (PRECEEDED BY CONCURRENT TEMOZOLZMIDE) ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2/DAY ORALLY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES. | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
414 | CMU0134 -iii-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - TEMOZOLOMIDE (POST RT) ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2/DAY ORALLY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
415 | CMU0134 -iii-d : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - TEMOZOLOMIDE (200MG) WITH STANDARD RT ; DAYS 1-5 - TEMOZOLOMIDE 200MG/M2, ORALLY | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
416 | CMU0134 -iv : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
417 | CMU0134 -iv-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) - VINCRISTINE + CISPLATIN + LOMUSTINE ; DAY 1 - LOMUSTINE 75MG/M2 ORALLY ; DAY 2 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS; ; DURING CRANIO-SPINAL RT | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
418 | CMU0134 -iv-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) - VINCRISTINE + CISPLATIN + CYCLOPHOSPHAMIDE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS ; DAYS 22, 23 - CYCLOPHOSPHAMIDE 1, 000MG/M2 IV. | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
419 | CMU0134 -v : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMAPRIMARY CNS LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
420 | CMU0134 -v-a : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPYHIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPY | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
421 | CMU0134 -v-a-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE + CYTARABINE ; DAY 1 - MTX 3.5G/M2 ; DAYS 2-3 - CYTARABINE 2G/M2 IV TWICE A DAY. | MEDICAL ONCOLOGY | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 |
422 | CMU0134 -v-a-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE + LEUCOVORIN + IFOSFAMIDE + MESNA ; DAY 1 - MTX 4GM/M2 IV, ; DAYS 2-5 - LEUCOVORIN 20-25MG IV (UPTO 40MG) ; DAYS 3-5 - IFOSFAMIDE 1.5GM/M2 IV + MESNA 400MG IV | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
423 | CMU0134 -v-b : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPY HIGH DOSE METHOTREXATE (MTX 2.5-4.0MG/M2) + CHEMOTHERAPY MONOCLONAL ANTIBODY | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
424 | CMU0134 -v-b-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + MTX + VINCRISTINE +PROCARBAZINE ; DAY 1 - RITUXIMAB 500MG/M2 IV ; DAY 2 - MTX 3.5MG/M2 IV PLUS VINCRISTINE 1.4MG/M2 ; PROCARBAZINE 100MG/M2/DAY ADMINISTERED FOR 7 DAYS WITH ODD-NUMBERED CYCLES | MEDICAL ONCOLOGY | 44000 | 44000 | 44000 | 44000 | 44000 | 44000 | 44000 | 44000 |
425 | CMU0134 -v-c : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE (MTX 8.0MG/M2) + CHEMOTHERAPY +/- MONOCLONAL ANTIBODY HIGH DOSE METHOTREXATE (MTX 8.0MG/M2) + CHEMOTHERAPY MONOCLONAL ANTIBODY | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
426 | CMU0134 -v-c-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE INDUCTION ; MTX 8G/M2 IV ; REPEAT EVERY 2 WEEKS UNTIL COMPLETE RESPONSE ACHIEVED OR MAX OF 8 CYCLES REACHED. ; | MEDICAL ONCOLOGY | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 |
427 | CMU0134 -v-c-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE CONSOLIDATION ; MTX 8G/M2 IV ADMINISTERED ; REPEAT EVERY 2 WEEKS FOR 2 CYCLES. | MEDICAL ONCOLOGY | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 |
428 | CMU0134 -v-c-3-i : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE MAINTANANCE (CYCLES 1-4) ; DAY 1 - MTX 8G/M2 IV, RITUXIMAB 375MG/M2 IV. ; REPEAT EVERY 4 WEEKS FOR 4 CYCLES | MEDICAL ONCOLOGY | 27600 | 27600 | 27600 | 27600 | 27600 | 27600 | 27600 | 27600 |
429 | CMU0134 -v-c-3-ii : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE MAINTANANCE (CYCLES 5-11) ; MTX 8G/M2 IV ADMINISTERED EVERY 4 WEEKS FOR 11 CYCLES. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES | MEDICAL ONCOLOGY | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 |
430 | CMU0134 -v-d : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
431 | CMU0134 -v-d-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN - INDUCTION ; DAY 1 - RITUXIMAB 375MG/M2 IV, FOLLOWED BY ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2 ORALLY DAILY, AFTER RITUXIMAB INFUSION. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 22700 | 22700 | 22700 | 22700 | 22700 | 22700 | 22700 | 22700 |
432 | CMU0134 -v-d-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN - MAINTANANCEDAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2 ORALLY DAILY. ; REPEAT CYCLE EVERY 4 WEEKS FOR 8 CYCLES. | MEDICAL ONCOLOGY | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 |
433 | CMU0134 -v-e : BRAIN CARCINOMA - MENINGIOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
434 | CMU0134 -v-e-1 : BRAIN CARCINOMA - MENINGIOMA - INTERFERON-ALFAINTERFERON-ALFA ; ALPHA-IFN 106 UNITS/M2 SC EVERY OTHER DAY FOR 4 WEEKS. ; REPEAT CYCLE EVERY 4 WEEKS. ; | MEDICAL ONCOLOGY | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 |
435 | CMU0134 -v-e-2 : BRAIN CARCINOMA - MENINGIOMA -SOMATOSTATIN ANALOG ; SANDOSTATIN LAR DEPOT 10-30MG IM ; REPEAT EVERY 4 WEEKS. ; | MEDICAL ONCOLOGY | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 |
436 | CMU0134 -v-e-3 : BRAIN CARCINOMA - MENINGIOMA - SUNITINIB ; DAYS 1-28 - SUNITINIB 50MG ORALLY DAILY. ; REPEAT CYCLE EVERY 42 DAYS. | MEDICAL ONCOLOGY | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 |
437 | CMU0135 : HEAD AND NECK CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
438 | CMU0135 -i : HEAD AND NECK CANCER - SQUAMOUS CELL CANCERS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
439 | CMU0135 -i-a : HEAD AND NECK CANCER - HIGH DOSE CISPLATIN ; CISPLATIN 100MG/M2 IV + CONCURRENT RADIOTHERAPY; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
440 | CMU0135 -i-b : HEAD AND NECK CANCER - CARBOPLATIN + INFUSIONAL 5-FU ; DAYS 1-4 - 5-FU 600MG/M2/DAY AS CONTINUOUS IV I, CARBOPLATIN 70MG/M2/DAY IV ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES (GIVEN CONCURRENTLY WITH RADIOTHERAPY). | MEDICAL ONCOLOGY | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 |
441 | CMU0135 -i-c : HEAD AND NECK CANCER - 5-FU + HYDROXYUREA ; DAY 1 - HYDROXYUREA 1, 000MG ORALLY EVERY 12 HOURS (11 DOSES/CYCLE), 5-FU 800MG/M2/DAY ; REPEAT EVERY OTHER WEEK FOR 7 CYCLES. WITH CONCURRENT RADIOTHERAPY | MEDICAL ONCOLOGY | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 |
442 | CMU0135 -i-d : HEAD AND NECK CANCER - CISPLATIN + PACLITAXEL ; DAY 1 - PACLITAXEL 30MG/M2 IV (EVERY MONDAY), ; DAY 2 - CISPLATIN 20MG/M2 IV (EVERY TUESDAY). ; REPEAT CYCLE EVERY WEEK FOR 7 CYCLES, WITH CONCURRENT RADIOTHERAPY | MEDICAL ONCOLOGY | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 |
443 | CMU0135 -i-e : HEAD AND NECK CANCER - CISPLATIN + INFUSIONAL 5-FU ; DAY 1 - CISPLATIN 60MG/M2 OVER ; DAYS 1-5 - 5-FU 800MG/M2/DAY ; REPEAT EVERY OTHER WEEK FOR 7 CYCLES. WITH CONCURRENT RADIOTHERAPY | MEDICAL ONCOLOGY | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 |
444 | CMU0135 -i-f : HEAD AND NECK CANCER - CARBOPLATIN + PACLITAXEL ; DAY 1 - PACLITAXEL 40-45MG/M2, CARBOPLATIN 100MG/M2 ; REPEAT CYCLE EVERY WEEK FOR 8 CYCLES, WITH CONCURRENT RADIOTHERAPY | MEDICAL ONCOLOGY | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 |
445 | CMU0135 -i-g : HEAD AND NECK CANCER - WEEKLY CISPLATIN ; CISPLATIN 40MG/M2 IV PER WEEK | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
446 | CMU0135 -i-h : HEAD AND NECK CANCER - CISPLATIN (FOR HIGH RISK OROPHARYNGEAL CARCINOMA) ; DAYS 1, 22, AND 43 - CISPLATIN 100MG/M2 IV + RADIOTHERAPY. | MEDICAL ONCOLOGY | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 |
447 | CMU0135 -ii : HEAD AND NECK CANCER - NASOPHARYNX CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
448 | CMU0135 -i-i : HEAD AND NECK CANCER - DOCETAXEL + CISPLATIN + 5-FU ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV, ; DAYS 1-5 - 5-FU 750MG/M2/DAY IV. ; REPEAT EVERY 3 WEEKS FOR UP TO 4 CYCLES. | MEDICAL ONCOLOGY | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 |
449 | CMU0135 -ii-a : NASOPHARYNX CANCER - CONCURRENT CISPLATIN FOLLOWED BY CONCURRENT CISPLATIN +5FUC ; | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
450 | CMU0135 -ii-a-1 : NASOPHARYNX CANCER - CONCURRENT CISPLATIN (FOLLOWED BY CONCURRENT CISPLATIN +5FU) ; DAY 1 - CISPLATIN 100MG/M2 IV; PLUS RADIOTHERAPY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES; FOLLOWED BY CONCURRENT CISPLATIN +5FU | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
451 | CMU0135 -ii-a-2 : NASOPHARYNX CANCER - CONCURRENT CISPLATIN +5FU - PRECEEDED BY (CONCURRENT CISPLATIN 3 CYCLES) ; DAYS 1-4 - CISPLATIN 80MG/M2/DAY, 5-FU 1, 000MG/M2/DAY IV ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 CYCLES | MEDICAL ONCOLOGY | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 |
452 | CMU0135 -ii-b : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN FOLLOWED BY CONCURRENT CARBOPLATIN +5FU | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
453 | CMU0135 -ii-b-1 : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN - (FOLLOWED BY CONCURRENT CARBOPLATIN +5FU) ; DAY 1 - CARBOPLATIN AUC 6MG/MIN/ML IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES; | MEDICAL ONCOLOGY | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 |
454 | CMU0135 -ii-b-2 : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN +5FU - PRECEEDED BY (CONCURRENT CARBOPLATIN ) ; DAY 1 - CARBOPLATIN AUC 5MG/MIN/ML IV ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES. | MEDICAL ONCOLOGY | 14200 | 14200 | 14200 | 14200 | 14200 | 14200 | 14200 | 14200 |
455 | CMU0135 -ii-c : NASOPHARYNX CANCER - CONCURRENT CISPLATIN ; CISPLATIN 40MG/M2 ; REPEAT WEEKLY FOR 7 CYCLES | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
456 | CMU0135 -ii-d : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN + 5-FU FOLLOWED BY CISPLATIN ; | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
457 | CMU0135 -ii-d-1 : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN + 5-FU - FOLLOWED BY CISPLATIN AFTER 3 CYCLES ; DAY 1 - DOCETAXEL 70MG/M2 IV, CISPLATIN 75MG/M2 IV ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY IV ; REPEAT EVERY WEEK FOR 3 CYCLES | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
458 | CMU0135 -ii-d-2 : NASOPHARYNX CANCER - CISPLATIN - WEEKLY - PRECEDED BY 3 CYCLES OF DOCETAXEL + 5-FU ; DAY 1 - CISPLATIN 100MG/M2; ; REPEAT EVERY 3 WEEKS, TILL RADIATION | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
459 | CMU0135 -ii-e : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
460 | CMU0135 -ii-e-1 : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN - FOLLOWED BY CISPLATIN AFTER 2 CYCLES ; DAY 1 - DOCETAXEL 75MG/M2 IV + CISPLATIN 75MG/M2 IV ; REPEAT EVERY 3 WEEKS FOR TWO CYCLES | MEDICAL ONCOLOGY | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 |
461 | CMU0135 -ii-e-2 : NASOPHARYNX CANCER - CISPLATIN - WEEKLY - PRECEDED BY 2 CYCLES OF DOCETAXEL + CISPLATIN ; CISPLATIN 40MG/M2 IV ; WEEKLY CONCURRENT WITH RADIOTHERAPY. | MEDICAL ONCOLOGY | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 |
462 | CMU0135 -ii-f : NASOPHARYNX CANCER - CISPLATIN + 5-FU ; DAY 1 - CISPLATIN 100MG/M2/DAY IV. ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY CONTINUOUS IV INFUSION FOR 4 DAYS. ; REPEAT CYCLE EVERY 3 WEEKS FOR A MINIMUM OF 6 CYCLES | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
463 | CMU0135 -i-j : HEAD AND NECK CANCER - PACLITAXEL + CISPLATIN+ INFUSIONAL 5-FU ; DAY 1 - PACLITAXEL 175MG/M2 ; DAY 2 - CISPLATIN 100MG/M2 ; DAY 2-6 - 5-FU 500MG/M2/DAY IV ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. | MEDICAL ONCOLOGY | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 |
464 | CMU0136 : RENAL CELL CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
465 | CMU0136 -a : RENAL CELL CARCINOMA - PAZOPANIB | MEDICAL ONCOLOGY | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 |
466 | CMU0136 -b : RENAL CELL CARCINOMA - SUNITINIB | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
467 | CMU0136 -c : RENAL CELL CARCINOMA - SORAFENIB | MEDICAL ONCOLOGY | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 |
468 | CMU0136 Ia : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY | MEDICAL ONCOLOGY | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 |
469 | CMU0136 Ib : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF. | MEDICAL ONCOLOGY | 30700 | 30700 | 30700 | 30700 | 30700 | 30700 | 30700 | 30700 |
470 | CMU0136 Ic : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - BEVACIZUMAB + IFN-ALPHA ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS + IFN-ALPHA. | MEDICAL ONCOLOGY | 70100 | 70100 | 70100 | 70100 | 70100 | 70100 | 70100 | 70100 |
471 | CMU0136 Id : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
472 | CMU0136 IIa : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - EVEROLIMUS ; EVEROLIMUS 10MG ORALLY ONCE DAILY | MEDICAL ONCOLOGY | 39100 | 39100 | 39100 | 39100 | 39100 | 39100 | 39100 | 39100 |
473 | CMU0136 IIb : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY | MEDICAL ONCOLOGY | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 |
474 | CMU0136 IIc : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
475 | CMU0136 IId : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF. | MEDICAL ONCOLOGY | 30700 | 30700 | 30700 | 30700 | 30700 | 30700 | 30700 | 30700 |
476 | CMU0136 IIe : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - BEVACIZUMAB ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS. | MEDICAL ONCOLOGY | 69600 | 69600 | 69600 | 69600 | 69600 | 69600 | 69600 | 69600 |
477 | CMU0136 IIIa : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF. | MEDICAL ONCOLOGY | 30700 | 30700 | 30700 | 30700 | 30700 | 30700 | 30700 | 30700 |
478 | CMU0136 IIIb : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - BEVACIZUMAB ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS. | MEDICAL ONCOLOGY | 69600 | 69600 | 69600 | 69600 | 69600 | 69600 | 69600 | 69600 |
479 | CMU0136 IIIc : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - EVEROLIMUS ; EVEROLIMUS 10MG ORALLY ONCE DAILY | MEDICAL ONCOLOGY | 39100 | 39100 | 39100 | 39100 | 39100 | 39100 | 39100 | 39100 |
480 | CMU0136 IIId : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - ERLOTINIB ; ERLOTINIB 150MG ORALLY ONCE DAILY | MEDICAL ONCOLOGY | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 |
481 | CMU0136 IIIe : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY | MEDICAL ONCOLOGY | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 |
482 | CMU0136 IIIf : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
483 | CMU0137 : UNKNOWN PRIMARY | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
484 | CMU0137 -i : UNKNOWN PRIMARY - ADENOCARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
485 | CMU0137 -i-a : UNKNOWN PRIMARY - ADENOCARCINOMA - PACLITAXEL + CARBOPLATIN + ETOPOSIDE ; DAY 1 - PACLITAXEL 200 MG/M 2 IV, CARBOPLATIN AUC 6 ; DAYS 1-10 - ETOPOSIDE 50 MG PO ALTERNATING WITH 100 MG DAILY ; REPEAT EVERY 21DAYS FOR 2-3 CYCLES; RESTAGE, CAN BE TREATED UPTO 8 CYCLES | MEDICAL ONCOLOGY | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 |
486 | CMU0137 -i-b : UNKNOWN PRIMARY - ADENOCARCINOMA - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 200 MG/M 2, CARBOPLATIN AUC 6 ; REPEAT CYCLE EVERY 3 WEEKS, MAXIMUM 8 CYCLES | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
487 | CMU0137 -i-c : UNKNOWN PRIMARY - ADENOCARCINOMA - DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 65MG/M2 IV, CARBOPLATIN AUC 6 ; REPEAT CYCLE EVERY 3 WEEKS, MAXIMUM 8 CYCLES. | MEDICAL ONCOLOGY | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 |
488 | CMU0137 -i-d : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + CISPLATIN ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAY 1 AND 8 - GEMCITABINE 1250MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 |
489 | CMU0137 -i-e : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + DOCETAXEL ; DAY 1 AND 8 - GEMCITABINE 1000MG/M2 IV OVER 30 MINUTES ; DAY 8 - DOCETAXEL 75MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR A MAXIMUM OF 6 CYCLES | MEDICAL ONCOLOGY | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 |
490 | CMU0137 -i-f : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + IRINOTECAN ; DAYS 1 AND 8 - IRINOTECAN 100MG/M2 IV, GEMCITABINE 1000MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES.RESTAGE EVERY 2-3 CYCLES | MEDICAL ONCOLOGY | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 |
491 | CMU0137 -i-g : UNKNOWN PRIMARY - ADENOCARCINOMA - MFOLFOX ; DAY 1 - OXALIPLATIN 85MG/M2 IV OVER 2 HOURS + LEUCOVORIN 400MG/M2 IV OVER 2 HOURS + 5-FU 400MG/M2 IV BOLUS THEN ; DAYS 1 AND 2 - 5-FU 1200MG/M2 (TOTAL 2400MG/M2 OVER 46-48 HOURS) IV CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS FOR 24 CYCLES | MEDICAL ONCOLOGY | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 |
492 | CMU0137 -i-h : UNKNOWN PRIMARY - ADENOCARCINOMA - CAPEOX ; DAY 1 - OXALIPLATIN 130MG/M2 IV OVER 2 HOURS ; DAY 1-14 - CAPECITABINE 850-1000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 16 CYCLES. | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
493 | CMU0137 -ii : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
494 | CMU0137 -i-i : UNKNOWN PRIMARY - ADENOCARCINOMA - IRINOTECAN + CARBOPLATIN ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAYS 1, 8, AND 15 - IRINOTECAN 60MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR UP TO 6 CYCLES | MEDICAL ONCOLOGY | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 |
495 | CMU0137 -ii-a : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA - PACLITAXEL + CISPLATIN + 5-FU ; PACLITAXEL 175 MG/M 2 IV, ; DAY 2 - CISPLATIN 100 MG/M 2 IV, ; DAY 5-FU (5-FLUOROURACIL) 500 MG/M 2/DAY IV ; REPEAT EVERY 21D | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
496 | CMU0137 -ii-b : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA - DOCETAXEL + CISPLATIN + 5-FU ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV. ; DAYS 1-5 - 5-FU 750MG/M2/DAY IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES. | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
497 | CMU0137 -ii-c : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -PACLITAXEL + CARBOPLATIN ; DAY 1 - CARBOPLATIN AUC 6MG PER MIN/ML IV OVER 30 MINUTES + PACLITAXEL 200MG/M2 IV OVER 3 HOURS. ; REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES IN RESPONDING PATIENTS AND FOR 6 CYCLES MAXIMUM IN PATIENTS WITH STABLE DISEASE | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
498 | CMU0137 -ii-d : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -CISPLATIN + GEMCITABINE ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAY 1 AND 8 - GEMCITABINE 1250MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
499 | CMU0137 -ii-e : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -MFOLFOX ; DAY 1 - OXALIPLATIN 85MG/M2 IV OVER 2 HOURS + LEUCOVORIN 400MG/M2 IV OVER 2 HOURS + 5-FU 400MG/M2 IV BOLUS THEN ; DAYS 1 AND 2 - 5-FU 1200MG/M2 (TOTAL 2400MG/M2 OVER 46-48 HOURS) IV CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS FOR 24 CYCLES. | MEDICAL ONCOLOGY | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 | 8400 |
500 | CMU0137 -ii-f : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -PACLITAXEL + CISPLATIN ; DAY 1 - PACLITAXEL 175MG/M2 IV + CISPLATIN 60MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS. | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
501 | CMU0137 -ii-g : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 75MG/M2 IV OVER 30 MINUTES + CARBOPLATIN AUC 5MG PER MIN/ML IV OVER 30 MINUTES. ; REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES | MEDICAL ONCOLOGY | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 |
502 | CMU0137 -ii-h : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CISPLATIN ; DAY 1 - DOCETAXEL 60MG/M2 IV + CISPLATIN 80MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 2 CYCLES AND AN ADDITIONAL 4 CYCLES UNTIL DISEASE PROGRESSION IS DEMONSTRATED | MEDICAL ONCOLOGY | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 |
503 | CMU0137 -iii : UNKNOWN PRIMARY - NEUROENDOCRINE TUMORS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
504 | CMU0137 -ii-i : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CISPLATIN ; DAY 1 - DOCETAXEL 75MG/M2 IV + CISPLATIN 75MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES. | MEDICAL ONCOLOGY | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 |
505 | CMU0137 -iii-b : UNKNOWN PRIMARY - NEUROENDOCRINE TUMORS - ETOPOSIDE + CISPLATIN ; DAYS 1-3 - ETOPOSIDE 100 MG/M 2 ; DAYS 2-3 - CISPLATIN 45 MG/M 2 IV ; REPEAT EVERY 28 DAYS | MEDICAL ONCOLOGY | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 |
506 | CMU0137 -ii-j : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -CISPLATIN + FLUOROURACIL ; DAYS 1-5 - CISPLATIN 20MG/M2 IV ; DAYS 1-5 - FLUOROURACIL 700MG/M2/DAY IV VIA CONTINUOUS INFUSION OVER 24 HOURS. ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 CYCLES. | MEDICAL ONCOLOGY | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 | 7400 |
507 | CMU0138 : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMACA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
508 | CMU0138 -a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - GEMCITABINE + CISPLATIN ; DAYS 1 AND 8 - CISPLATIN 25MG/M2 IV, GEMCITABINE 1, 000MG/M2 IV ; REPEAT EVERY 21 DAYS FOR 4 CYCLES, RE-EVALUATE AND CONTINUE AN ADDITIONAL 4 CYCLES IF WARRANTED | MEDICAL ONCOLOGY | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 |
509 | CMU0138 -b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV | MEDICAL ONCOLOGY | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 |
510 | CMU0138 -c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - CAPECITABINE ; CAPECITABINE ORAL ; REPEAT EVERY 21 DAYS | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
511 | CMU0139 : PANCREAS CARCINOMAPANCREAS CARCINOMA - | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
512 | CMU0139 -i : PANCREAS CARCINOMA - PATIENTS WITH RESECTABLE PANCREATIC CANCER - LOCALLY ADVANCED ; | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
513 | CMU0139 -i-a : PANCREAS CARCINOMA - PATIENTS WITH RESECTABLE PANCREATIC CANCER - LOCALLY ADVANCED GEMCITABINE ; DAYS 1, 8, AND 15 - GEMCITABINE 1, 000MG/M2 IV ; REPEAT EVERY 4 WEEKS FOR SIX CYCLES | MEDICAL ONCOLOGY | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 |
514 | CMU0139 -ii : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
515 | CMU0139 -ii-a : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - 5-FU + LEUCOVORIN ; DAYS 1-5 - LEUCOVORIN 20MG/M2 IV, 5-FU 425MG/M2 IV ; REPEAT CYCLE EVERY 4 WEEKS | MEDICAL ONCOLOGY | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 |
516 | CMU0139 -ii-b : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - GEMCITABINE & 5FU ; PRIOR TO CHEMORADIATION - ; DAYS 1, 8 AND 15 - GEMCITABINE 1, 000MG/M2 IV; INITIATE 1-2 WEEKS PRIOR TO CHEMORADIATION (50.4GY + 5-FU 250MG/M2/DAY). ; AFTER CHEMORADIATION - ; DAYS 1, 8 AND 15 - GEMCITABINE 1, 000MG/M2 IV; INITIATE 3-5 WEEKS FOLLOWING CHEMORADIATION. ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 MONTHS. | MEDICAL ONCOLOGY | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 |
517 | CMU0139 -ii-c : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - CONTINUOUS INFUSION 5-FU (WITH RADIATION) ; PRIOR TO CHEMORADIATION - ; DAYS 1-21 - 5-FU 250MG/M2/DAY CONTINUOUS IV INFUSION; INITIATE 1-2 WEEKS PRIOR TO CHEMORADIATION (50.4GY + 5-FU 250MG/M2/DAY). ; AFTER CHEMORADIATION - ; DAYS 1-28 - 5-FU 250MG/M2/DAY CONTINUOUS IV INFUSION; INITIATE 3-5 WEEKS FOLLOWING CHEMORADIATION. ; REPEAT CYCLE EVERY 6 WEEKS FOR 3 MONTHS. | MEDICAL ONCOLOGY | 21800 | 21800 | 21800 | 21800 | 21800 | 21800 | 21800 | 21800 |
518 | CMU0139 -iii : PANCREAS CARCINOMA - NEOADJUVANT THERAPY - NEOADJUVANT THERAPY | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
519 | CMU0139 -iii-a : PANCREAS CARCINOMA - NEOADJUVANT THERAPY - CAPECITABINECAPECITABINE ; CAPECITABINE ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 52 WEEKS. | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
520 | CMU0140 : PERI AMPULLARY CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
521 | CMU0140 -a : PERI AMPULLARY CARCINOMA - 5-FU ; FLUOROURACIL 425 MG/M2 ADMINISTERED ON DAYS 1 TO 5 AND 29-33 | MEDICAL ONCOLOGY | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 |
522 | CMU0141 : NEURO ENDOCRINE CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
523 | CMU0141 -a : NEURO ENDOCRINE CARCINOMA - ALL NECS ARE COVERED UNDER ORGAN CANCERS. IF UNCOVERED - UNLISTED ONLY. | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
524 | CMU0142 : SARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
525 | CMU0142 -i : SARCOMA - GASTROINTESTINAL STROMAL TUMOR - GIST | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
526 | CMU0142 -i-a : SARCOMA - GASTROINTESTINAL STROMAL TUMOR - GIST - IMATINIB ; IMATINIB 400MG ORALLY ONCE DAILY TO TWICE DAILY | MEDICAL ONCOLOGY | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 |
527 | CMU0142 -ii : SARCOMA - SOFT TISSUE SARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
528 | CMU0142 -ii-a : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN + DACARBAZINE (AD) ; DAYS 1-4 - DOXORUBICIN 60MG/M2 + DACARBAZINE 750MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS | MEDICAL ONCOLOGY | 12100 | 12100 | 12100 | 12100 | 12100 | 12100 | 12100 | 12100 |
529 | CMU0142 -ii-b : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN + IFOSFAMIDE + MESNA ; DAYS 1 AND 2 - DOXORUBICIN 30MG/M2/DAY IV, IFOSFAMIDE 3, 750MG/M2/DAY IV, MESNA 750MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS | MEDICAL ONCOLOGY | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 |
530 | CMU0142 -ii-c : SARCOMA - SOFT TISSUE SARCOMA - MESNA + DOXORUBICIN + IFOSFAMIDE + DACARBAZINE (MAID) ; DAYS 1-3 - DOXORUBICIN 20MG/M2/DAY, IFOSFAMIDE 2, 500MG/M2/DAY, DACARBAZINE 300MG/M2/DAY IV ; DAYS 1-4 - MESNA 2, 500MG/M2/DAY IV FOR 84 TO 96 HOURS. ; REPEAT CYCLE EVERY 3 WEEKS. | MEDICAL ONCOLOGY | 11300 | 11300 | 11300 | 11300 | 11300 | 11300 | 11300 | 11300 |
531 | CMU0142 -ii-d : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE + EPIRUBICIN + MESNA ; DAYS 1 AND 2 - EPIRUBICIN 60MG/M2/DAY IV ; DAYS 1-5 - IFOSFAMIDE 1.8G/M2/DAY IV + MESNA. ; REPEAT CYCLE EVERY 3 WEEKS FOR 5 CYCLES. | MEDICAL ONCOLOGY | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 |
532 | CMU0142 -ii-e : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + DOCETAXEL ; DAYS 1 AND 8 - GEMCITABINE 900MG/M2 IV ; DAY 8 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
533 | CMU0142 -ii-f : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + VINORELBINE ; DAYS 1 AND 8 - VINORELBINE 25MG/M2 IV, GEMCITABINE 800MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS | MEDICAL ONCOLOGY | 15500 | 15500 | 15500 | 15500 | 15500 | 15500 | 15500 | 15500 |
534 | CMU0142 -ii-g : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + DACARBAZINE ; DAY 1 - GEMCITABINE 1, 800MG/M2 IV + DACARBAZINE 500MG/M2 IV. ; REPEAT CYCLE EVER 2 WEEKS FOR A TOTAL OF 12 CYCLES; | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
535 | CMU0142 -ii-h : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN ; DOXORUBICIN 60-75MG/M2 IV ; ONCE EVERY 3 WEEKS | MEDICAL ONCOLOGY | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 |
536 | CMU0142 -ii-i : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE ; DAYS 1-3 - IFOSFAMIDE 2, 000-3, 000MG/M2/DAY IV FOR 3 TO 4 DAYS + MESNA ; REPEAT EVERY 3 WEEKS. | MEDICAL ONCOLOGY | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 | 10500 |
537 | CMU0142 -ii-j : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE ; DAY 1 - IFOSFAMIDE 5, 000MG/M2 + MESNA 5, 000MG/M2 IV ; DAY 2 - MESNA 400-600MG/M2 IV ; IFOSFAMIDE, MESNA ; REPEAT EVERY 3 WEEKS | MEDICAL ONCOLOGY | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 |
538 | CMU0142 -ii-k : SARCOMA - SOFT TISSUE SARCOMA - EPIRUBICIN ; EPIRUBICIN 160MG/M2 IV ; REPEAT EVERY 3 WEEKS | MEDICAL ONCOLOGY | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 |
539 | CMU0142 -ii-l : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE ; DAYS 1 AND 8 - GEMCITABINE 1, 200MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS. | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
540 | CMU0142 -ii-m : SARCOMA - SOFT TISSUE SARCOMA - DACARBAZINE (I) ; DACARBAZINE 250MG/M2/DAY IV FOR 5 DAYS ; REPEAT EVERY 3 WEEKS. | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
541 | CMU0142 -ii-n : SARCOMA - SOFT TISSUE SARCOMA - DACARBAZINE (II) ; DACARBAZINE 800-1, 000MG/M2 IV ; REPEAT EVERY 3 WEEKS. | MEDICAL ONCOLOGY | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
542 | CMU0142 -ii-o : SARCOMA - SOFT TISSUE SARCOMA - LIPOSOMAL DOXORUBICIN ; LIPOSOMAL DOXORUBICIN 30-50MG/M2 IV ; REPEAT EVERY 4 WEEKS. | MEDICAL ONCOLOGY | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 |
543 | CMU0142 -ii-p : SARCOMA - SOFT TISSUE SARCOMA - TEMOZOLOMIDE ; TEMOZOLOMIDE 200MG/M2 ORALLY TWICE DAILY FOR 5 DAYS, FOLLOWED BY 9 DOSES OF 90MG/M2 ORALLY ; REPEAT EVERY 4 WEEKS | MEDICAL ONCOLOGY | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 |
544 | CMU0143 : PRIMITIVE NEURO ECTODERMAL TUMOR | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
545 | CMU0143 -a : PRIMITIVE NEURO ECTODERMAL TUMOR - WEEKLY VINCRISTINE ; VINCRISTINE 1.5MG/M2 IV, MAX 2MG ; FOR 5 TO 6 WEEKS | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
546 | CMU0143 -b : PRIMITIVE NEURO ECTODERMAL TUMOR - VINCRISTINE + CISPLATIN + LOMUSTINE ; DURING CRANIOSPINAL RADIOTHERAPY (RT) ; DAY 1 - LOMUSTINE 75MG/M2 ORALLY ; DAY 2 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS; UP TO MAX 8 DOSES | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
547 | CMU0143 -c : PRIMITIVE NEURO ECTODERMAL TUMOR - VINCRISTINE + CISPLATIN + CYCLOPHOSPHAMIDE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV, MAX 2MG ; DAYS 22, 23 - CYCLOPHOSPHAMIDE 1, 000MG/M2 IV | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
548 | CMU0144 : ANAL CANAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
549 | CMU0144 -a : ANAL CANAL CANCER - 5-FU + MITOMYCIN ; DAYS 1-4 AND 29-32 - 5-FU 1, 000MG/M2/DAY IV ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS (MAXIMUM 20MG PER COURSE), WITH CONCURRENT RADIOTHERAPY | MEDICAL ONCOLOGY | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 |
550 | CMU0144 -b : ANAL CANAL CANCER - CAPECITABINE + MITOMYCIN (I) ; DAYS 1-5 - CAPECITABINE 825MG/M2 ORALLY TWICE DAILY WEEKLY FOR 6 WEEKS, ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS, WITH CONCURRENT RADIOTHERAPY. | MEDICAL ONCOLOGY | 8500 | 8500 | 8500 | 8500 | 8500 | 8500 | 8500 | 8500 |
551 | CMU0144 -c : ANAL CANAL CANCER - CAPECITABINE + MITOMYCIN (II) ; DAYS 1-5 - CAPECITABINE 825MG/M2 ORALLY TWICE DAILY WEEKLY FOR 6 WEEKS, ; DAY 1 - MITOMYCIN 12MG/M2 IV BOLUS, WITH CONCURRENT RADIOTHERAPY | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
552 | CMU0144 -d : ANAL CANAL CANCER - CISPLATIN + 5-FU ; DAYS 1-5 - 5-FU 1, 000MG/M2/DAY IV ; DAY 2 - CISPLATIN 100MG/M2 IV ; REPEAT CYCLE EVERY 4 WEEKS, WITH CONCURRENT RADIOTHERAPY | MEDICAL ONCOLOGY | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 |
553 | CMU0145 : CA-PENIS | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
2361 | CMU0975 : SURGERY/CHEMOTHERAPY/RADIOTHERAPY FOR ALL LEUKEMIAS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2362 | CMU0975 A : ALL LEUKEMIA( CHEMOTHERAPHY) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2363 | CMU0975 A-I : CHRONIC MYELOID LEUKEMIA (CML) - CHRONIC MYELOID LEUKEMIA (CML) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2364 | CMU0975 A-II : ACUTE MYELOID LEUKEMIA (AML) - ACUTE MYELOID LEUKEMIA (AML) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2365 | CMU0975 A-II-a : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE 1 - AGE | MEDICAL ONCOLOGY | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 |
2366 | CMU0975 A-I-i-a : CHRONIC MYELOID LEUKEMIA (CML) - IMATINIB - LOW TO INTERMEDIATE RISK - IMATINIB 400MG ORALLY DAILY | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
2367 | CMU0975 A-II-b : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE - AGE | MEDICAL ONCOLOGY | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 |
2368 | CMU0975 A-I-i-b : CHRONIC MYELOID LEUKEMIA (CML) - NILOTINIB - LOW TO INTERMEDIATE RISK - NILOTINIB 300MG ORALLY TWICE DAILY | MEDICAL ONCOLOGY | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 |
2369 | CMU0975 A-II-c : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE 2 - AGE | MEDICAL ONCOLOGY | 10900 | 10900 | 10900 | 10900 | 10900 | 10900 | 10900 | 10900 |
2370 | CMU0975 A-II-d : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE (HIGH DOSE) - AGE | MEDICAL ONCOLOGY | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 |
2371 | CMU0975 A-II-e : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE (HIGH DOSE) - AGE | MEDICAL ONCOLOGY | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 |
2372 | CMU0975 A-II-f : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN (90MG) + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; DAUNORUBICIN 45-90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. | MEDICAL ONCOLOGY | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 |
2373 | CMU0975 A-II-g : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; IDARUBICIN 12MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. | MEDICAL ONCOLOGY | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 |
2374 | CMU0975 A-II-h : ACUTE MYELOID LEUKEMIA (AML) - MITOXANTRONE + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; MITOXANTRONE 12MG/M2 IV), DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. | MEDICAL ONCOLOGY | 10800 | 10800 | 10800 | 10800 | 10800 | 10800 | 10800 | 10800 |
2375 | CMU0975 A-III : CHRONICLYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2376 | CMU0975 A-II-i : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-10; CYTARABINE 20MG SC TWICE DAILY | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
2377 | CMU0975 A-I-ii : CHRONICMYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2378 | CMU0975 A-I-ii-a : CML - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - INDUCTION - 4 WEEKS OF STANDARD INDUCTION CHEMOTHERAPY - CYCLOPHOSPHAMIDE 1200 MG/M 2 (800 MG/M2 - OLDER THAN 60 Y) IV ON DAY 1 +DAUNORUBICIN 45 MG/M 2/DAY (30 MG/M 2/DAY - OLDER THAN 60 Y) IV ON DAYS 1-3 +VINCRISTINE 2 MG IV ON DAYS 1, 8, 15, AND 22 +PREDNISONE 60 MG/M 2/DAY PO ON DAYS 1-21 (DAYS 1-7- OLDER THAN 60 Y) + L-ASPARAGINASE 6000 U/M 2 SC ON DAYS 5, 8, 11, 15, 18, AND 22 | MEDICAL ONCOLOGY | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 |
2379 | CMU0975 A-III-a-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 1 - DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY | MEDICAL ONCOLOGY | 1200 | 1200 | 1200 | 1200 | 1200 | 1200 | 1200 | 1200 |
2380 | CMU0975 A-III-a-ii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 3 - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY | MEDICAL ONCOLOGY | 21800 | 21800 | 21800 | 21800 | 21800 | 21800 | 21800 | 21800 |
2381 | CMU0975 A-III-a-iii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 4-8 - DAY 1; RITUXIMAB 500MG/M2 IV, DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY. | MEDICAL ONCOLOGY | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 |
2382 | CMU0975 A-III-a-iv : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - MAINTANANCE - RITUXIMAB - RITUXIMAB AT DOSE OF 375MG/M2 IV EVERY 2 MONTHS FOR 2 YEARS | MEDICAL ONCOLOGY | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 |
2383 | CMU0975 A-III-b : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB DAY 1, 8, 15, AND 22 - DAY 1, 8, 15, AND 22; RITUXIMAB 375MG/M2/DAY IV. | MEDICAL ONCOLOGY | 85500 | 85500 | 85500 | 85500 | 85500 | 85500 | 85500 | 85500 |
2384 | CMU0975 A-I-ii-b : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - IMATINIB - IMATINIB 400MG ORALLY DAILY | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
2385 | CMU0975 A-III-c : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - CHLORAMBUCIL - DAYS 1-28; CHLORAMBUCIL 0.4MG/KG/DAY WITH AN INCREASE TO 0.8MG/KG ORALLY DAILY. REPEAT CYCLE EVERY 28 DAYS FOR 12 CYCLES | MEDICAL ONCOLOGY | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
2386 | CMU0975 A-I-ii-c : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY | MEDICAL ONCOLOGY | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 |
2387 | CMU0975 A-III-d-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE + RITUXIMAB (CYCLE -1) - DAY 0; RITUXIMAB 375MG/M2 IV, DAYS 1 AND 2; BENDAMUSTINE 70MG/M2 IV. REPEAT NEXT CYCLE AFTER 28 DAYS | MEDICAL ONCOLOGY | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 |
2388 | CMU0975 A-III-d-ii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE + RITUXIMAB (CYCLES 2-6) - RITUXIMAB 500MG/M2 ON DAY 1 AND BENDAMUSTINE - 90MG/M2. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE | MEDICAL ONCOLOGY | 32300 | 32300 | 32300 | 32300 | 32300 | 32300 | 32300 | 32300 |
2389 | CMU0975 A-III-d-iii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE (70MG) (CYCLE -1) - DAYS 1 AND 2; BENDAMUSTINE 70MG/M2 IV. REPEAT NEXT CYCLE AFTER 28 DAYS | MEDICAL ONCOLOGY | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 |
2390 | CMU0975 A-III-d-iv : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE (90 MG) (CYCLES 2-6) - DAY 1 - BENDAMUSTINE 90MG/M2. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
2391 | CMU0975 A-III-e : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - FLUDARABINE + CYCLOPHOSPHAMIDE + RITUXIMAB (FCR) - DAY 1; RITUXIMAB 375MG OR 500/M2 IV, DAYS 1-3; FLUDARABINE 25MG/M2/DAY IV PLUS CYCLOPHOSPHAMIDE 250MG/M2/DAY IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE | MEDICAL ONCOLOGY | 27200 | 27200 | 27200 | 27200 | 27200 | 27200 | 27200 | 27200 |
2392 | CMU0975 A-III-f : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - FLUDARABINE + RITUXIMAB (FR) - DAYS 1-5; FLUDARABINE 25MG/M2 IV, DAY 1; RITUXIMAB 50MG/M2 IV, DAY 3; RITUXIMAB 325MG/M2 IV, DAY 5; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES WITH RITUXIMAB GIVEN AT A DOSE OF 375MG/M2 ON DAY 1 OF SUBSEQUENT CYCLES. | MEDICAL ONCOLOGY | 57800 | 57800 | 57800 | 57800 | 57800 | 57800 | 57800 | 57800 |
2393 | CMU0975 A-III-g : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - ALEMTUZUMAB + RITUXIMAB - DAY 1; ALEMTUZUMAB 3MG IV, DAY 2; ALEMTUZUMAB 10MG IV, DAY 3, 10, 12, 17, 19, 24, AND 26; ALEMTUZUMAB 30MG IV | MEDICAL ONCOLOGY | 92700 | 92700 | 92700 | 92700 | 92700 | 92700 | 92700 | 92700 |
2394 | CMU0975 A-III-h : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - ALEMTUZUMAB WITHOUT RITUXIMAB - DAY 1; ALEMTUZUMAB 3MG IV, DAY 2; ALEMTUZUMAB 10MG IV, DAY 3, 10, 12, 17, 19, 24, AND 26; ALEMTUZUMAB 30MG IV | MEDICAL ONCOLOGY | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 |
2395 | CMU0975 A-III-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - HIGH-DOSE METHYLPREDNISOLONE + RITUXIMAB - DAYS 1-3; METHYLPREDNISOLONE 1G/M2 IV, DAYS 1, 8, 15, AND 22; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 3 CYCLES | MEDICAL ONCOLOGY | 88400 | 88400 | 88400 | 88400 | 88400 | 88400 | 88400 | 88400 |
2396 | CMU0975 A-I-iii : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2397 | CMU0975 A-I-iii-a : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN (90MG/M2)+ CYTARABINE - < 60 YEARS, DAYS 1-3; DAUNORUBICIN 90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV | MEDICAL ONCOLOGY | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 |
2398 | CMU0975 A-I-iii-b : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN + CYTARABINE + CLADRIBINE - AGE | MEDICAL ONCOLOGY | 10900 | 10900 | 10900 | 10900 | 10900 | 10900 | 10900 | 10900 |
2399 | CMU0975 A-I-iii-c : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN + CYTARABINE (HIGH DOSE) - AGE | MEDICAL ONCOLOGY | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 | 17600 |
2400 | CMU0975 A-I-iii-d : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN (90MG) + CYTARABINE - AGE >60 YEARS - DAYS 1-3; DAUNORUBICIN 45-90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. | MEDICAL ONCOLOGY | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 | 12900 |
2401 | CMU0975 A-I-iii-e : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IDARUBICIN + CYTARABINE (HIGH DOSE) - DAYS 1-3; IDARUBICIN 12MG/M2, DAYS 1-6; HIGH-DOSE CYTARABINE 2G/M2 IV EVERY 12 HOURS, OR DAYS 1-4; HIGH-DOSE CYTARABINE 3G/M2 IV EVERY 12 HOURS | MEDICAL ONCOLOGY | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 |
2402 | CMU0975 A-I-iii-f : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IDARUBICIN + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; IDARUBICIN 12MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. | MEDICAL ONCOLOGY | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 | 24400 |
2403 | CMU0975 A-I-iii-g : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - MITOXANTRONE + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; MITOXANTRONE 12MG/M2 IV), DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. | MEDICAL ONCOLOGY | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 |
2404 | CMU0975 A-I-iii-h : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IMATINIB - IMATINIB 400MG ORALLY DAILY | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
2405 | CMU0975 A-I-iii-i : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY | MEDICAL ONCOLOGY | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 |
2406 | CMU0975 A-III-j : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - HIGH-DOSE METHYLPREDNISOLONE - DAYS 1-3; METHYLPREDNISOLONE 1G/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 3 CYCLES | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
2407 | CMU0975 A-II-j : ACUTE MYELOID LEUKEMIA (AML) - DECITABINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-5; DECITABINE 20MG/M2 IV FOR A 4-WEEK CYCLE. | MEDICAL ONCOLOGY | 26300 | 26300 | 26300 | 26300 | 26300 | 26300 | 26300 | 26300 |
2408 | CMU0975 A-II-k : ACUTE MYELOID LEUKEMIA (AML) - AZACYTIDINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-7; 5-AZACYTIDINE 75MG/M2 IV EVERY 28 DAYS | MEDICAL ONCOLOGY | 81400 | 81400 | 81400 | 81400 | 81400 | 81400 | 81400 | 81400 |
2409 | CMU0975 A-II-l : ACUTE MYELOID LEUKEMIA (AML) - HYDROXYUREA - AGE ?60 YEARS, HYDROXYUREA 10-70MG/KG/DAY ORALLY IN DIVIDED DOSES. | MEDICAL ONCOLOGY | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 |
2410 | CMU0975 A-II-m : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE - HIGH DOSE - AGE | MEDICAL ONCOLOGY | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 | 10200 |
2411 | CMU0975 A-II-n : ACUTE MYELOID LEUKEMIA (AML) - CLADRIBINE + CYTARABINE + IDARUBICIN + GCSF - DAYS 1-5; CLADRIBINE 5MG/M2 IV, DAYS 1-5; CYTARABINE 2G/M2 IV, DAYS 0-5; GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) 300MCG SC, DAYS 1-3; IDARUBICIN 10MG/M2 IV. | MEDICAL ONCOLOGY | 89400 | 89400 | 89400 | 89400 | 89400 | 89400 | 89400 | 89400 |
2412 | CMU0975 A-II-o : ACUTE MYELOID LEUKEMIA (AML) - CLADRIBINE + CYTARABINE + MITOXANTRONE + GCSF - DAYS 1-5; CLADRIBINE 5MG/M2 IV, DAYS 1-5; CYTARABINE 2G/M2 IV, DAYS 0-5; GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) 300MCG SC, DAYS 1-3; MITOXANTRONE 10MG/M2 IV. | MEDICAL ONCOLOGY | 42700 | 42700 | 42700 | 42700 | 42700 | 42700 | 42700 | 42700 |
2413 | CMU0975 A-II-p : ACUTE MYELOID LEUKEMIA (AML) - FLUDARABINE + CYTARABINE + IDARUBICIN + GCSF -DAYS 1-5; FLUDARABINE 30MG/M2 IV OVER 0.5 HOURS, DAYS 1-5; CYTARABINE 2G/M2 IV OVER 4 HOURS, DAYS 0 TO POLYMORPHONUCLEAR RECOVERY (>0.5 X 109/L); G-CSF 5MCG/KG OR 300MCG/M2. (G-CSF MAY ALSO START ON DAY +6 UNTIL ENGRAFTMENT.) + DAYS 1-3; IDARUBICIN 10MG/M2 IV. | MEDICAL ONCOLOGY | 70100 | 70100 | 70100 | 70100 | 70100 | 70100 | 70100 | 70100 |
2414 | CMU0975 A-II-q : ACUTE MYELOID LEUKEMIA (AML) - ETOPOSIDE +CYTARABINE+MITOXANTRONE - ETOPOSIDE +CYTARABINE+MITOXANTRONE, DAYS 1-6; ETOPOSIDE 80MG/M2 IV OVER 1 HOUR, DAYS 1-6; CYTARABINE 1G/M2 IV OVER 6 HOURS + DAYS 1-6; MITOXANTRONE 6MG/M2 IV BOLUS | MEDICAL ONCOLOGY | 13900 | 13900 | 13900 | 13900 | 13900 | 13900 | 13900 | 13900 |
2415 | CMU0975 A-II-r : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE SC - DAYS 1-10; CYTARABINE 20MG SC TWICE DAILY | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
2416 | CMU0975 A-II-s : ACUTE MYELOID LEUKEMIA (AML) - AZACYTIDINE - DAYS 1-7; 5-AZACYTIDINE 75MG/M2 IV EVERY 28 DAYS | MEDICAL ONCOLOGY | 81400 | 81400 | 81400 | 81400 | 81400 | 81400 | 81400 | 81400 |
2417 | CMU0975 A-II-t : ACUTE MYELOID LEUKEMIA (AML) - DECITABINE - DAYS 1-5; DECITABINE 20MG/M2 IV EVERY 28 DAYS. | MEDICAL ONCOLOGY | 26800 | 26800 | 26800 | 26800 | 26800 | 26800 | 26800 | 26800 |
2418 | CMU0975 A-IV : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2419 | CMU0975 A-IV-i : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2420 | CMU0975 A-IV-i-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 INDUCTION PHASE; INDUCTION; 4 WEEKS OF STANDARD INDUCTION CHEMOTHERAPY; CYCLOPHOSPHAMIDE 1200 MG/M 2 (800 MG/M 2 IF PATIENTS OLDER THAN 60 Y) IV ON DAY 1 +DAUNORUBICIN 45 MG/M 2/DAY (30 MG/M 2/DAY IF PATIENTS OLDER THAN 60 Y) IV ON DAYS 1 - 3 +VINCRISTINE 2 MG IV ON DAYS 1, 8, 15, AND 22 +PREDNISONE 60 MG/M 2/DAY PO ON DAYS 1 - 21 (DAYS 1 - 7 IF PATIENTS OLDER THAN 60 Y); | MEDICAL ONCOLOGY | 14000 | 14000 | 14000 | 14000 | 14000 | 14000 | 14000 | 14000 |
2421 | CMU0975 A-IV-i-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 - (3 WEEKS); DAY 1 - METHOTREXATE (MTX) INTRATHECALLY (IT), ETOPOSIDE 100MG/M2/DAY INTRAVENOUSLY (IV), IFOSFAMIDE 3.4G/M2/DAY IV; DAYS 1 - 21 - IMATINIB 340MG/M2/DAY ORALLY; DAYS 6 - 15 - FILGRASTIM 5G/KG/DAY SUBCUTANEOUSLY (SC) +/- IMATINIB; DAYS 8 AND 15 - CNS LEUKEMIA ONLY - MTX IT, HYDROCORTISONE IT, CYTARABINE IT; | MEDICAL ONCOLOGY | 18000 | 18000 | 18000 | 18000 | 18000 | 18000 | 18000 | 18000 |
2422 | CMU0975 A-IV-i-a-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 (3 WEEKS); DAY 1 - AGE ADJUSTED - MTX IT, HYDROCORTISONE IT, CYTARABINE IT + MTX 5G/M2 IV OVER 24 HOURS; DAYS 1 - 21 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF PATIENT DOES NOT ACHIEVE COUNT RECOVERY WITHIN 2 WEEKS OF LAST DOSE OF PREVIOUS COURSE); DAYS 2 - 3 - LEUCOVORIN 75MG/M2 36 HOURS AFTER MTX, FOLLOWED BY 15MG/M2 IV OR ORALLY EVERY 6 HOURS FOR 6 DOSES + CYTARABINE 3G/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES; DAYS 4 - 13 - FILGRASTIM 5G/KG/DAY SC | MEDICAL ONCOLOGY | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 | 20200 |
2423 | CMU0975 A-IV-i-a-4 : ALL - PH(+) AYA - COG AALL-0031 REINDUCTION ; DAY 1 - VINCRISTINE 1.5MG/M2 IV + AGE ADJUSTED - MTX IT, HYDROCORTISONE IT, CYTARABINE IT; DAYS 1 - 2 - DAUNORUBICIN 45MG/M2/DAY IV BOLUS; DAYS 1 - 21 - DEXAMETHASONE 6MG/M2/DAY ORALLY +/- IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAYS 3 - 4 - CYCLOPHOSPHAMIDE 250MG/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES + MESNA 125MG/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES; DAYS 4, 6, 8, 10, 12, 15, 17, 19, AND 21 - L - ASPARAGINASE 6, 000 IU/M2 INTRAMUSCULARLY (IM); DAYS 5 - 14 - FILGRASTIM 5G/KG/DAY SC; DAYS 8 AND 15 - VINCRISTINE 1.5MG/M2 IV; DAY 15 - MTX IT, HYDROCORTISONE IT, CYTARABINE IT. | MEDICAL ONCOLOGY | 26600 | 26600 | 26600 | 26600 | 26600 | 26600 | 26600 | 26600 |
2424 | CMU0975 A-IV-i-a-5 : ALL - PH(+) AYA - COG AALL-0031 INTENSIFICATION; DAY 1 - MTX, HYDROCORTISONE, CYTARABINE - IT + MTX IV; DAYS 1-63 - IMATINIB ORAL; DAYS 2-3 - LEUCOVORIN ; DAY 8 - MTX IV; DAYS 9-10 - LEUCOVORIN; DAY 15 - MTX , HYDROCORTISONE , CYTARABINE - IT; DAYS 15-19 - ETOPOSIDE + CYCLOPHOSPHAMIDE + MESNA - IV; DAYS 20-29 - FILGRASTIM SC; DAYS 36-37 - CYTARABINE; DAY 37 - L - ASPARAGINASE IM +/- IMATINIB; DAYS 43-44 - CYTARABINE IV; DAY 44 - L - ASPARAGINASE IM +/- IMATINIB; | MEDICAL ONCOLOGY | 43500 | 43500 | 43500 | 43500 | 43500 | 43500 | 43500 | 43500 |
2425 | CMU0975 A-IV-i-a-6 : ALL - PH(+) AYA - COG AALL-0031 MAINTENANCE CYCLES 1-4 (8 WEEKS); DAY 1 - MTX, HYDROCORTISONE, CYTARABINE - IT + VINCRISTINE + MTX IV; DAYS 1 - 5 - DEXA; DAYS 1 - 56 - IMATINIB; DAY 2 - LEUCOVORIN 36 HOURS AFTER MTX; DAYS 8, 15, AND 22 - MTX ORAL; DAYS 8 - 28 - 6-MP; DAY 29 - MTX, HYDROCORTISONE, CYTARABINE - IT + VINCRISTINE IV; DAYS 29 - 33 - DEXA; DAYS 29 - 40 - IMATINIB; DAYS 36 - 40 - ETOPOSIDE + CYCLOPHOSPHAMIDE IV; DAYS 41 - 50 - FILGRASTIM SC; | MEDICAL ONCOLOGY | 37400 | 37400 | 37400 | 37400 | 37400 | 37400 | 37400 | 37400 |
2426 | CMU0975 A-IV-i-a-7 : ALL - PH(+) AYA -COG AALL-0031 MAINTENANCE CYCLES 5-12 (8 WEEKS); CYCLE 5 ONLY - CRANIAL IRRADIATION 12 GY; DAY 1 - VINCRISTINE 1.5MG/M2 IV; DAYS 1 - 5 - DEXAMETHASONE 6MG/M2/DAY ORALLY; DAYS 1 - 14 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAYS 8, 15, AND 22 - MTX 20MG/M2/WEEK ORALLY; DAYS 8 - 28 - 6 - MP 75MG/M2/DAY; DAY 29 - VINCRISTINE 1.5MG/M2 IV; DAYS 29 - 33 - DEXAMETHASONE 6MG/M2/DAY ORALLY; DAYS 29 - 42 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAY 36 - MTX 20MG/M2/WEEK ORALLY; DAYS 36 - 56 - 6 - MP 75MG/M2/DAY; DAYS 43 AND 50 - MTX 20MG/M2/WEEK ORALLY; | MEDICAL ONCOLOGY | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 |
2427 | CMU0975 A-IV-i-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 (CYCLES 1 AND 3 ONLY) - RITUXIMAB 375MG/M2 IV. | MEDICAL ONCOLOGY | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 |
2428 | CMU0975 A-IV-i-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4); HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV | MEDICAL ONCOLOGY | 65500 | 65500 | 65500 | 65500 | 65500 | 65500 | 65500 | 65500 |
2429 | CMU0975 A-IV-i-b-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY | MEDICAL ONCOLOGY | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 |
2430 | CMU0975 A-IV-i-b-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 | MEDICAL ONCOLOGY | 14100 | 14100 | 14100 | 14100 | 14100 | 14100 | 14100 | 14100 |
2431 | CMU0975 A-IV-i-b-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION II - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 8 - 63 - IMATINIB 600MG ORALLY; DAY 29 - MTX 15MG IT, CYTARABINE 40MG IT, DEXAMETHASONE 4MG IT | MEDICAL ONCOLOGY | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 |
2432 | CMU0975 A-IV-i-b-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION III - PRETREATMENT FOR 7 DAYS - PREDNISONE AT INCREASING DOSES FROM 10 - 40MG/M2/DAY; DAYS 1 - 45 - IMATINIB 800MG ORALLY DAILY + PREDNISONE 40MG/M2 DAILY | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
2433 | CMU0975 A-IV-i-b-7 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) MAINTENANCE - MTX WEEKLY + 6 - MP DAILY + VINCRISTINE PULSE MONTHLY + PREDNISONE PULSE MONTHLY FOR 2 TO 3 YEARS. | MEDICAL ONCOLOGY | 10400 | 10400 | 10400 | 10400 | 10400 | 10400 | 10400 | 10400 |
2434 | CMU0975 A-IV-i-c-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS INDUCTION PHASE - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAYS 8 - 63 - IMATINIB 600MG ORALLY DAILY; DAY 29 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT. | MEDICAL ONCOLOGY | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 |
2435 | CMU0975 A-IV-i-c-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION I - DAY 1 - MTX 1G/M2 IV OVER 24 HOURS + MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; DAYS 1 - 3 - METHYLPREDNISOLONE 50MG IV OVER 1 HOUR × 2 DOSES; DAYS 2 AND 3 - CYTARABINE 2G/M2 IV OVER 3 HOURS; REPEAT FOR 4 CYCLES. | MEDICAL ONCOLOGY | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 |
2436 | CMU0975 A-IV-i-c-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION II - DAY 1 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; REPEAT FOR 4 CYCLES; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY. | MEDICAL ONCOLOGY | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 |
2437 | CMU0975 A-IV-i-c-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS MAINTENANCE - DAY 1 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 5 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY; REPEAT EVERY 4 WEEKS UP TO 2 YEARS FROM THE DATE OF COMPLETE REMISSION. | MEDICAL ONCOLOGY | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 |
2438 | CMU0975 A-IV-i-c-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - IMATINIB - IMATINIB 400MG ORALLY DAILY | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
2439 | CMU0975 A-IV-i-c-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY | MEDICAL ONCOLOGY | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 |
2440 | CMU0975 A-IV-ii : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2441 | CMU0975 A-IV-ii-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV | MEDICAL ONCOLOGY | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 |
2442 | CMU0975 A-IV-ii-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV | MEDICAL ONCOLOGY | 65500 | 65500 | 65500 | 65500 | 65500 | 65500 | 65500 | 65500 |
2443 | CMU0975 A-IV-ii-a-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY | MEDICAL ONCOLOGY | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 |
2444 | CMU0975 A-IV-ii-a-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES | MEDICAL ONCOLOGY | 14100 | 14100 | 14100 | 14100 | 14100 | 14100 | 14100 | 14100 |
2445 | CMU0975 A-IV-ii-a-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION II - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 8 - 63 - IMATINIB 600MG ORALLY; DAY 29 - MTX 15MG IT, CYTARABINE 40MG IT, DEXAMETHASONE 4MG IT. | MEDICAL ONCOLOGY | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 | 15900 |
2446 | CMU0975 A-IV-ii-a-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION III - PRETREATMENT FOR 7 DAYS - PREDNISONE AT INCREASING DOSES FROM 10 - 40MG/M2/DAY; DAYS 1 - 45 - IMATINIB 800MG ORALLY DAILY + PREDNISONE 40MG/M2 DAILY | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
2447 | CMU0975 A-IV-ii-a-7 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) MAINTENANCE - MTX WEEKLY + 6 - MP DAILY + VINCRISTINE PULSE MONTHLY + PREDNISONE PULSE MONTHLY FOR 2 TO 3 YEARS. | MEDICAL ONCOLOGY | 10400 | 10400 | 10400 | 10400 | 10400 | 10400 | 10400 | 10400 |
2448 | CMU0975 A-IV-ii-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS INDUCTION PHASE - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAYS 8 - 63 - IMATINIB 600MG ORALLY DAILY; DAY 29 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT. | MEDICAL ONCOLOGY | 16400 | 16400 | 16400 | 16400 | 16400 | 16400 | 16400 | 16400 |
2449 | CMU0975 A-IV-ii-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION I - DAY 1 - MTX 1G/M2 IV OVER 24 HOURS + MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; DAYS 1 - 3 - METHYLPREDNISOLONE 50MG IV OVER 1 HOUR × 2 DOSES; DAYS 2 AND 3 - CYTARABINE 2G/M2 IV OVER 3 HOURS; REPEAT FOR 4 CYCLES. | MEDICAL ONCOLOGY | 12700 | 12700 | 12700 | 12700 | 12700 | 12700 | 12700 | 12700 |
2450 | CMU0975 A-IV-ii-b-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION II - DAY 1 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; REPEAT FOR 4 CYCLES; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY. | MEDICAL ONCOLOGY | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 |
2451 | CMU0975 A-IV-ii-b-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS MAINTENANCE - DAY 1 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 5 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY; REPEAT EVERY 4 WEEKS UP TO 2 YEARS FROM THE DATE OF COMPLETE REMISSION. | MEDICAL ONCOLOGY | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 |
2452 | CMU0975 A-IV-ii-b-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - IMATINIB - IMATINIB 400MG ORALLY DAILY | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
2453 | CMU0975 A-IV-ii-b-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY | MEDICAL ONCOLOGY | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 |
2454 | CMU0975 A-IV-ii-c : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CORTICOSTEROIDS + TKIS - PRETREATMENT | MEDICAL ONCOLOGY | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 |
2455 | CMU0975 A-IV-iii : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2456 | CMU0975 A-IV-iii-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 INDUCTION - CORTICOSTEROID PRE-PHASE - 1-7 DAYS BEFORE INDUCTION THERAPY; PREDNISONE 60MG/M2/DAY, 4-7 DAYS BEFORE INDUCTION THERAPY; MTX 15MG IT. INDUCTION I - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2/DAY + VINCRISTINE 2MG IV, DAYS 1-3; DAUNORUBICIN 50MG/M2/DAY, DAYS 1-14; PREDNISONE 60MG/M2/DAY, DAY 8; VINCRISTINE 2MG IV + L-ASPARAGINASE 6, 000IU/M2/DAY, DAYS 10 AND 12; L-ASPARAGINASE 6, 000IU/M2/DAY, DAY 15; VINCRISTINE 2MG IV, DAY 15; FOR GOOD EARLY RESPONDERS; CYCLOPHOSPHAMIDE 750MG/M2/DAY. | MEDICAL ONCOLOGY | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 |
2457 | CMU0975 A-IV-iii-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 SALVAGE - DAYS 1-3; IDARUBICIN 12MG/M2/DAY, DAYS 1-4; CYTARABINE 2G/M2/12 HOURS, DAY 9; FILGRASTIM TO MYELOID RECOVERY. | MEDICAL ONCOLOGY | 30200 | 30200 | 30200 | 30200 | 30200 | 30200 | 30200 | 30200 |
2458 | CMU0975 A-IV-iii-a-3 : ALL - PH(-) AYA - GRAALL-2003 CONSOLIDATION - BLOCKS 1, 4, AND 7; - DAYS 1 AND 2; CYTARABINE 2G/M2/12 HOURS + DEXAMETHASONE 10MG/12 HOURS, DAY 3; L-ASPARAGINASE 10, 000IU/M2/DAY, DAYS 7-13; FILGRASTIM TO MYELOID RECOVERY. BLOCKS 2, 5, AND 8 - DAY 15; MTX 3G/M2 CONTINUOUS INFUSION + VINCRISTINE 2MG IV + 6-MP 60MG/M2/DAY, DAY 16; L-ASPARAGINASE 10, 000IU/M2/DAY, DAYS 16-21; 6-MP 60MG/M2/DAY, DAYS 22-27; FILGRASTIM TO MYELOID RECOVERY. BLOCKS 3, 6, AND 9 - DAY 29; MTX 25MG/M2/DAY, DAYS 29 AND 30; CYCLOPHOSPHAMIDE 500MG/M2/DAY + ETOPOSIDE 75MG/M2/DAY, DAY 31; FILGRASTIM TO MYELOID RECOVERY. TO BE APPROVED 3 TIMES (BLOCKS - 1, 2, 3; BLOCKS - 4, 5, 6; BLOCKS - 7, 8, 9 | MEDICAL ONCOLOGY | 32300 | 32300 | 32300 | 32300 | 32300 | 32300 | 32300 | 32300 |
2459 | CMU0975 A-IV-iii-a-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 LATE INTENSIFICATION BETWEEN CONSOLIDATION BLOCKS 6 AND 7 (FOR PATIENTS IN COMPLETE REMISSION [CR] AFTER THE FIRST INDUCTION COURSE) - DAY 1; VINCRISTINE 2MG IV, DAYS 1-3; DAUNORUBICIN 30MG/M2/DAY, DAYS 1-14; PREDNISONE 60MG/M2/DAY | MEDICAL ONCOLOGY | 16300 | 16300 | 16300 | 16300 | 16300 | 16300 | 16300 | 16300 |
2460 | CMU0975 A-IV-iii-a-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 LATE INTENSIFICATION BETWEEN CONSOLIDATION BLOCKS 6 AND 7 (FOR PATIENTS IN CR AFTER SALVAGE COURSE) - DAYS 1-3; IDARUBICIN 9MG/M2/DAY, DAYS 1-4; CYTARABINE 2G/M2/12 HOURS, DAY 9; FILGRASTIM TO MYELOID RECOVERY. | MEDICAL ONCOLOGY | 28600 | 28600 | 28600 | 28600 | 28600 | 28600 | 28600 | 28600 |
2461 | CMU0975 A-IV-iii-a-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 MAINTENANCE | MEDICAL ONCOLOGY | 59800 | 59800 | 59800 | 59800 | 59800 | 59800 | 59800 | 59800 |
2462 | CMU0975 A-IV-iii-b : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CNS THERAPY-TREATMENT OF PATIENTS WITH INITIAL CNS INVOLVEMENT | MEDICAL ONCOLOGY | 22200 | 22200 | 22200 | 22200 | 22200 | 22200 | 22200 | 22200 |
2463 | CMU0975 A-IV-iii-v : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CCG-1961 | MEDICAL ONCOLOGY | 19200 | 19200 | 19200 | 19200 | 19200 | 19200 | 19200 | 19200 |
2464 | CMU0975 A-IV-iv : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2465 | CMU0975 A-IV-iv-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CALGB 8811 (LARSON REGIMEN) INDUCTION | MEDICAL ONCOLOGY | 19000 | 19000 | 19000 | 19000 | 19000 | 19000 | 19000 | 19000 |
2466 | CMU0975 A-IV-iv-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CALGB 8811 (LARSON REGIMEN) CONSOLIDATION | MEDICAL ONCOLOGY | 17500 | 17500 | 17500 | 17500 | 17500 | 17500 | 17500 | 17500 |
2467 | CMU0975 A-IV-iv-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - HYPER-CVAD WITH OR WITHOUT RITUXIMAB CYCLE 1, 3, 5, 7 - DAYS 1 - 3 - CYCLOPHOSPHAMIDE IV EVERY 12 HOURS + MESNA CONTINUOUS IV INFUSION STARTING 1 HOUR BEFORE CYCLOPHOSPHAMIDE UNTIL 12 HOURS AFTER COMPLETION OF CYCLOPHOSPHAMIDE; DAYS 1 - 4 AND 11 - 14 - DEXAMETHASONE ORALLY DAILY, +/-; DAYS 1 AND 8 - RITUXIMABIV; DAY 4 - DOXORUBICIN IV OVER 24 HOURS; DAYS 4 AND 11 - VINCRISTINE IV | MEDICAL ONCOLOGY | 64000 | 64000 | 64000 | 64000 | 64000 | 64000 | 64000 | 64000 |
2468 | CMU0975 A-IV-iv-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - HYPER-CVAD WITH OR WITHOUT RITUXIMAB CYCLE 2, 4, 6, 8 - DAY 1 - METHOTREXATE IV OVER 2 HOURS FOLLOWED BY CONTINUOUS IV INFUSION OVER 22 HOURS FOLLOWED BY LEUCOVORIN IV EVERY 6 HOURS STARTING 12 HOURS AFTER COMPLETION OF MTX; DAYS 2 - 3 - CYTARABINE (IV OVER 2 HOURS EVERY 12 HOURS, +/-; DAYS 1 AND 8 - RITUXIMAB 375MG/M2 IV; CNS PROPHYLAXIS; DAY 2 - METHOTREXATE 12MG IT; DAY 8 - CYTARABINE 100MG IT. | MEDICAL ONCOLOGY | 59700 | 59700 | 59700 | 59700 | 59700 | 59700 | 59700 | 59700 |
2469 | CMU0976 A : ALL LYMPHOMACHEMOTHERAPHY | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2470 | CMU0976 A-I : HODGKINS LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2471 | CMU0976 A-I-a : HODGKINSLYMPHOMA - ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES. REPEAT CYCLE EVERY 4 WEEKS FOR 2-4 CYCLES OR UPTO 6 CYCLES - MAY BE FOLLOWED BY ESCALATED BEACOPP | MEDICAL ONCOLOGY | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 |
2472 | CMU0976 A-I-b : HODGKINSLYMPHOMA - ESCALATED BEACOPP - DAY 1; CYCLOPHOSPHAMIDE 1, 250MG/M2 IV OVER 60 MINUTES + DOXORUBICIN 35MG/M2 IV PUSH, DAYS 1-3; ETOPOSIDE 200MG/M2 IV OVER 2 HOURS | MEDICAL ONCOLOGY | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 | 7500 |
2473 | CMU0976 A-I-c : HODGKINSLYMPHOMA - ABVD + RITUXIMAB (CYLED EVERY 4 WEEKS) - | MEDICAL ONCOLOGY | 24300 | 24300 | 24300 | 24300 | 24300 | 24300 | 24300 | 24300 |
2474 | CMU0976 A-I-d-i : HODGKINS LYMPHOMA - ABVD + RITUXIMAB (1 CYCLE - WEEKLY RITUXIMAB 4 DOSES) FOLLOWED BY ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES, DAYS 1, 8, 15, AND 22; RITUXIMAB 375MG/M2 IV FOR CYCLE 1 ONLY. REPEAT ABVD CYCLE EVERY 4 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION (OR ) 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION | MEDICAL ONCOLOGY | 87200 | 87200 | 87200 | 87200 | 87200 | 87200 | 87200 | 87200 |
2475 | CMU0976 A-I-d-ii : HODGKINS LYMPHOMA - ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES. REPEAT CYCLE EVERY 4 WEEKS FOR 2-4 CYCLES OR UPTO 6 CYCLES - MAY BE FOLLOWED BY ESCALATED BEACOPP | MEDICAL ONCOLOGY | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 |
2476 | CMU0976 A-I-e-i : HODGKINS LYMPHOMA - CHOP + RITUXIMAB - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, DAY 1; RITUXIMAB 375MG/M2 IV, REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 |
2477 | CMU0976 A-I-e-ii : HODGKINS LYMPHOMA - CHOP - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
2478 | CMU0976 A-I-f-i : HODGKINS LYMPHOMA - CVP +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 |
2479 | CMU0976 A-I-f-ii : HODGKINS LYMPHOMA - CVP - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
2480 | CMU0976 A-I-g : HODGKINSLYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 7 DAYS FOR 4 WEEKS WITH OR WITHOUT MAINTENANCE RITUXIMAB (375MG/M2 IV ONCE WEEKLY FOR 4 WEEKS EVERY 6 MONTHS FOR UP TO 2 YEARS) | MEDICAL ONCOLOGY | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 |
2481 | CMU0976 A-II : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2482 | CMU0976 A-II-a : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BORTEZOMIB + DEXAMETHASONE - DAYS 1, 4, 8, AND 11; BORTEZOMIB 1.3MG/M2 IV, DAYS 1, 4, 8, AND 11; DEXAMETHASONE 40MG IV. REPEAT FOR 4 CONSECUTIVE CYCLES AS INDUCTION THERAPY AND FOLLOW WITH 4 MAINTENANCE CYCLES, EACH GIVEN 3 MONTHS APART. | MEDICAL ONCOLOGY | 57900 | 57900 | 57900 | 57900 | 57900 | 57900 | 57900 | 57900 |
2483 | CMU0976 A-II-b : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE + RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 IV + DOXORUBICIN 50MG/M2 IV + VINCRISTINE 1.4MG/M2 (MAX 2MG) IV + RITUXIMAB 375MG/M2 IV, DAYS 1-5; PREDNISONE 100MG ORALLY. REPEAT EVERY 3 WEEKS FOR 6 CYCLES | MEDICAL ONCOLOGY | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 |
2484 | CMU0976 A-II-c : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 7 DAYS FOR 4 WEEKS | MEDICAL ONCOLOGY | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 |
2485 | CMU0976 A-II-d : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - RITUXIMAB + CYCLOPHOSPHAMIDE + PREDNISONE - DAY 1; RITUXIMAB 375MG/M2 IV + CYCLOPHOSPHAMIDE 1, 000MG/M2 IV, DAYS 1-5; PREDNISONE 100MG ORALLY. REPEAT EVERY 21 DAYS FOR 6 CYCLES | MEDICAL ONCOLOGY | 21900 | 21900 | 21900 | 21900 | 21900 | 21900 | 21900 | 21900 |
2486 | CMU0976 A-II-e : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - RITUXIMAB + CYCLOPHOSPHAMIDE + DEXAMETHASONE - DAY 1; DEXAMETHASONE 20MG IV FOLLOWED BY RITUXIMAB 375MG/M2 IV, DAYS 1-5; CYCLOPHOSPHAMIDE 100MG/M2 ORALLY TWICE DAILY. REPEAT EVERY 21 DAYS FOR 6 MONTHS | MEDICAL ONCOLOGY | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 |
2487 | CMU0976 A-II-f-i : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB (WEEKS 1 AND 2) - THALIDOMIDE 200MG ORALLY DAILY | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
2488 | CMU0976 A-II-f-ii : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB (WEEKS 3-50) - THALIDOMIDE 400MG ORALLY DAILY | MEDICAL ONCOLOGY | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 |
2489 | CMU0976 A-II-f-iii : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB (WEEKS 50-52) - THALIDOMIDE 400MG ORALLY DAILY | MEDICAL ONCOLOGY | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 |
2490 | CMU0976 A-II-f-iv : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB WEEKS 2-5 AND 13-16 - RITUXIMAB 375MG/M2 IV ONCE WEEKLY FOR A TOTAL OF 8 INFUSIONS AS ADD-ON | MEDICAL ONCOLOGY | 20400 | 20400 | 20400 | 20400 | 20400 | 20400 | 20400 | 20400 |
2491 | CMU0976 A-II-g-i : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BENDAMUSTINE WITH OR WITHOUT RITUXIMAB DAYS 1-2; BENDAMUSTINE 90MG/M2 IV, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 4 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 |
2492 | CMU0976 A-II-g-ii : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BENDAMUSTINE - RITUXIMAB - DAYS 1-2; BENDAMUSTINE 90MG/M2 IV, REPEAT EVERY 4 WEEKS FOR 4 CYCLES. | MEDICAL ONCOLOGY | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 |
2493 | CMU0976 A-II-h-i : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CLADRIBINE WITH OR WITHOUT RITUXIMAB - DAYS 1-5; CLADRIBINE 0.1MG/KG SUBCUTANEOUS INJECTION, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 4 WEEKS FOR 4 CYCLES | MEDICAL ONCOLOGY | 27500 | 27500 | 27500 | 27500 | 27500 | 27500 | 27500 | 27500 |
2494 | CMU0976 A-II-h-ii : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CLADRIBINE - RITUXIMAB - DAYS 1-5; CLADRIBINE 0.1MG/KG SUBCUTANEOUS INJECTION. REPEAT EVERY 4 WEEKS FOR 4 CYCLES | MEDICAL ONCOLOGY | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 |
2495 | CMU0976 A-III : NON HODGKINS LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2496 | CMU0976 A-II-i : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BENDAMUSTINE - DAYS 1-2; BENDAMUSTINE 90MG/M2 IV | MEDICAL ONCOLOGY | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 |
2497 | CMU0976 A-III-i : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2498 | CMU0976 A-III-i-a-1 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLE 1 - DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS, DAYS 1-5; CYCLOPHOSPHAMIDE 200MG/M2 IV, DAYS 1-7; PREDNISONE 60MG/M2 ORALLY. | MEDICAL ONCOLOGY | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 | 9400 |
2499 | CMU0976 A-III-i-a-2 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLES 2 (BEGINNING DAY 8) - DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS PROPHYLAXIS - DAYS 1-5; IFOSFAMIDE 800MG/M2 IV + DEXAMETHASONE 10MG/M2 IV | MEDICAL ONCOLOGY | 69400 | 69400 | 69400 | 69400 | 69400 | 69400 | 69400 | 69400 |
2500 | CMU0976 A-III-i-a-3 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLES 3, 5, AND 7 - DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS PROPHYLAXIS, DAYS 1-5; CYCLOPHOSPHAMIDE 200MG/M2 IV + DEXAMETHASONE 10MG/M2 IV | MEDICAL ONCOLOGY | 34800 | 34800 | 34800 | 34800 | 34800 | 34800 | 34800 | 34800 |
2501 | CMU0976 A-III-i-a-4 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLES 4, AND 6. DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS PROPHYLAXIS, DAYS 1-5; IFOSFAMIDE 800MG/M2 IV + DEXAMETHASONE 10MG/M2 IV, DAY 1; METHOTREXATE 1.5G/M2 IV (WITH LEUCOVORIN RESCUE) + VINCRISTINE 2MG IV, DAYS 4 AND 5; CYTARABINE 1G/M2 IV + ETOPOSIDE 80MG/M2 IV, DAY 8; 375MG/M2 IV. DELIVER CYCLES EVERY 21 DAYS. | MEDICAL ONCOLOGY | 38200 | 38200 | 38200 | 38200 | 38200 | 38200 | 38200 | 38200 |
2502 | CMU0976 A-III-i-b : NHL - BURKITT LYMPHOMA - CODOX-M (ORIGINAL OR MODIFIED) (CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE WITH INTRATHECAL MTX + CYTARABINE, FOLLOWED BY SYSTEMIC MTX AND CYTARABINE) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE + DOXORUBICIN, DAYS 2-5; CYCLOPHOSPHAMIDE IV, DAYS 1, 3; CYTARABINE INTRATHECAL, DAYS 1, 8; VINCRISTINE IV, DAY 10; MTX IV 1 HOUR, THEN INFUSION OVER 23 HOURS, DAY 11; LEUCOVORIN IV, EVERY 6 HOURS, DAY 13; G-CSF SC DAILY, DAY 15; MTX INTRATHECAL | MEDICAL ONCOLOGY | 39800 | 39800 | 39800 | 39800 | 39800 | 39800 | 39800 | 39800 |
2503 | CMU0976 A-III-i-c-1 : NHL - BURKITT LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 1 & 2) - DAY 1; RITUXIMAB 375MG/M2 IV DAYS 1-4; ETOPOSIDE 50MG/M2 IV INFUSION + DOXORUBICIN 10MG/M2 IV INFUSION + VINCRISTINE 0.4MG/M2 IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORAL BD, DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL | MEDICAL ONCOLOGY | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 |
2504 | CMU0976 A-III-i-c-2 : NHL - BURKITT LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + MTX - IT+ RITUXIMAB (CYCLES 3-6) - DAY 1; RITUXIMAB 375MG/M2 IV DAYS 1-4; ETOPOSIDE 50MG/M2 IV INFUSION + DOXORUBICIN 10MG/M2 IV INFUSION + VINCRISTINE 0.4MG/M2 IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORAL BD. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG UNTIL ANC >5, 000/uL, DAYS 1 AND 5 ; MTX 12MG - IT REPEAT EVERY 3 WEEKS FOR 6 CYCLES | MEDICAL ONCOLOGY | 27700 | 27700 | 27700 | 27700 | 27700 | 27700 | 27700 | 27700 |
2505 | CMU0976 A-III-i-d-1 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV | MEDICAL ONCOLOGY | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 |
2506 | CMU0976 A-III-i-d-2 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV | MEDICAL ONCOLOGY | 65000 | 65000 | 65000 | 65000 | 65000 | 65000 | 65000 | 65000 |
2507 | CMU0976 A-III-i-d-3 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
2508 | CMU0976 A-III-i-d-4 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES | MEDICAL ONCOLOGY | 13600 | 13600 | 13600 | 13600 | 13600 | 13600 | 13600 | 13600 |
2509 | CMU0976 A-III-i-e-1 : NHL - BURKITT LYMPHOMA - CODOX-M ALTERNATED WITH IVAC- CODOX-M (ORIGINAL OR MODIFIED) - DAY 1- CYCLOPHOSPHAMIDE + DOXORUBICIN - IV, DAYS 2-5- CYCLOPHOSPHAMIDE IV, DAYS 1, 3- CYTARABINE IT, DAYS 1, 8; VINCRISTINE IV, DAY 10; MTX IV 1 HOUR, THEN INFUSION FOR 23 HOURS, DAY 11; LEUCOVORIN IV - 6TH HOURLY; DAY 13- G-CSF SC DAILY, DAY 15; MTX - IT DAY 16- LEUCOVORIN ORAL G, +/- DAY 1; RITUXIMAB IV. REPEAT FOR 4 CYCLES ALTERNATE BETWEEN CODOX-M AND IVAC | MEDICAL ONCOLOGY | 39800 | 39800 | 39800 | 39800 | 39800 | 39800 | 39800 | 39800 |
2510 | CMU0976 A-III-i-e-2 : NHL - BURKITT LYMPHOMA - CODOX-M ALTERNATED WITH IVAC - IVAC (IFOSFAMIDE + CYTARABINE + ETOPOSIDE) AND IT MTX +/- RITUXIMAB - DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES. DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, + MESNA 360MG/M2, DAY 5; MTX 12MG IT DAY 6; LEUCOVORIN 15MG ORAL - MTX, DAY 7; G-CSF 5uG/KG SC DAILY UNTIL GRANULOCYTE COUNT >/=1 X 109/L, +/- DAY 1; RITUXIMAB 375 MG/M2 IV. REPEAT FOR 4 CYCLES ALTERNATE BETWEEN CODOX-M AND IVAC. | MEDICAL ONCOLOGY | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 |
2511 | CMU0976 A-III-i-f : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - RICE (RITUXIMAB + IFOSFAMIDE + CARBOPLATIN + ETOPOSIDE) - DAY 1; RITUXIMAB 375MG/M2 IV, DAY 2; IFOSFAMIDE 5, 000MG/M2 AND MESNA 5, 000MG/M2 IV + CARBOPLATIN AUC 5 MG / MIN/ML (MAXIMUM 800MG) IV, DAY 1-3; ETOPOSIDE 100MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS. | MEDICAL ONCOLOGY | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 |
2512 | CMU0976 A-III-i-g : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - RIVAC (RITUXIMAB + IFOSFAMIDE + CYTARABINE + ETOPOSIDE) - DAY 1; RITUXIMAB 375MG/M2 IV, DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES, DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, +MESNA 360MG/M2, DAY 5; METHOTREXATE 12MG INTRATHECALLY | MEDICAL ONCOLOGY | 37400 | 37400 | 37400 | 37400 | 37400 | 37400 | 37400 | 37400 |
2513 | CMU0976 A-III-i-h : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - RGDP (RITUXIMAB + GEMCITABINE + DEXAMETHASONE + CISPLATIN) - DAY 1; RITUXIMAB 375MG/M2 IV, DAY 1 AND 8; GEMCITABINE 1, 000MG/M2 IV, DAY 1-3; CISPLATIN 25MG/M2 IV, DAY 1-4; DEXAMETHASONE 40MG IV. REPEAT CYCLE EVERY 3 WEEKS. | MEDICAL ONCOLOGY | 27500 | 27500 | 27500 | 27500 | 27500 | 27500 | 27500 | 27500 |
2514 | CMU0976 A-III-ii : NON HODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - NON HODGKIN LYMPHOMA -- ADULT T-CELL LEUKEMIA / LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2515 | CMU0976 A-III-i-i : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - HDAC + RITUXIMAB - DAYS 1, 3, AND 5; HIGH-DOSE CYTARABINE 3G/M2 IV EVERY 12 HOURS, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT FOR 4 CYCLES | MEDICAL ONCOLOGY | 23700 | 23700 | 23700 | 23700 | 23700 | 23700 | 23700 | 23700 |
2516 | CMU0976 A-III-ii-a-1 : NON HODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - ZIDOVUDINE + ALPHA-INTERFERON (INDUCTION) - ZIDOVUDINE 1G ORALLY DAILY + ALPHA-INTERFERON 9 MILLION UNITS SC DAILY FOR 2 MONTHS, FOLLOWED BY MAINTENANCE THERAPY | MEDICAL ONCOLOGY | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 |
2517 | CMU0976 A-III-ii-a-2 : NON HODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - ZIDOVUDINE + ALPHA-INTERFERON (MAINTENANCE THERAPY) - ZIDOVUDINE 600MG ORALLY DAILY + ALPHA-INTERFERON 4.5 MILLION UNITS SC DAILY FOR 1 MONTH, REPEAT 12 MONTHS | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
2518 | CMU0976 A-III-ii-b : NONHODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
2519 | CMU0976 A-III-ii-c : NONHODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - CHOEP - DAYS 1-4; ETOPOSIDE 50MG/M2/DAY CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2/DAY CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2/DAY CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY DAILY, DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV OVER 15 MINUTES. REPEAT CYCLE EVERY 3 WEEKS FOR 6-8 CYCLES. | MEDICAL ONCOLOGY | 9100 | 9100 | 9100 | 9100 | 9100 | 9100 | 9100 | 9100 |
2520 | CMU0976 A-III-ii-d : NONHODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) - DAYS 1-4 - ETOPOSIDE 50MG/M2/DAY CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2/DAY CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2/DAY CONTINUOUS IV INFUSION, DAYS 1-5- PREDNISONE 60MG/M2 ORAL DAILY, DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV OVER 15 MINUTES. REPEAT CYCLE EVERY 3 WEEKS FOR 6-8 CYCLES. ADJUST DOSES BASED ON ANC. | MEDICAL ONCOLOGY | 7300 | 7300 | 7300 | 7300 | 7300 | 7300 | 7300 | 7300 |
2521 | CMU0976 A-III-iii : NONHODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2522 | CMU0976 A-III-iii-a : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CDE (CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE) + RITUXIMAB - DAYS 1-4; CYCLOPHOSPHAMIDE 187.5-200MG/M2 IV + DOXORUBICIN 12.5MG/M2 IV + ETOPOSIDE 60MG/M2 IV, DAY 1; RITUXIMAB 375MG/M2 IV JUST BEFORE CDE REGIMEN. REPEAT CYCLE EVERY 4 WEEKS FOR A MAXIMUM OF 6 CYCLES. | MEDICAL ONCOLOGY | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 |
2523 | CMU0976 A-III-iii-b-1 : NHL - DIFFUSE LARGE B CELL LYMPHOMA - CODOX-M ALTERNATED WITH IVAC (CODOX-M) CODOX-M (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE MTX ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYCLOPHOSPHAMIDE + DOXORUBICIN IV, DAYS 2-5; CYCLOPHOSPHAMIDE IV, DAYS 1, 3; CYTARABINE -IT, DAYS 1, 8-VINCRISTINE IV, DAY 10; MTX IV, DAY 11; LEUCOVORIN, DAY 13; G-CSF SC DAILY, DAY 15; MTX -IT, DAY 16; LEUCOVORIN ORAL, +/- DAY 1; RITUXIMAB IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS. | MEDICAL ONCOLOGY | 49100 | 49100 | 49100 | 49100 | 49100 | 49100 | 49100 | 49100 |
2524 | CMU0976 A-III-iii-b-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CODOX-M ALTERNATED WITH IVAC (IVAC) CODOX-M/IVAC (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE METHOTREXATE ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES. DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, +MESNA 360MG/M2, DAY 5; METHOTREXATE 12MG INTRATHECALLY, DAY 6; LEUCOVORIN 15MG ORALLY 24 HOURS AFTER INTRATHECAL MTX, DAY 7; G-CSF 5uG/KG SC DAILY UNTIL ABSOLUTE GRANULOCYTE COUNT >/=1 X 109/L, +/- DAY 1; RITUXIMAB 375 MG/M2 IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS. | MEDICAL ONCOLOGY | 45000 | 45000 | 45000 | 45000 | 45000 | 45000 | 45000 | 45000 |
2525 | CMU0976 A-III-iii-c-1 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 1&2) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL | MEDICAL ONCOLOGY | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 |
2526 | CMU0976 A-III-iii-c-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 3-6) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL, DAYS 1 AND 5; METHOTREXATE 12MG INTRATHECALLY. REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES | MEDICAL ONCOLOGY | 27700 | 27700 | 27700 | 27700 | 27700 | 27700 | 27700 | 27700 |
2527 | CMU0976 A-III-iii-d-1 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV | MEDICAL ONCOLOGY | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 |
2528 | CMU0976 A-III-iii-d-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV | MEDICAL ONCOLOGY | 65000 | 65000 | 65000 | 65000 | 65000 | 65000 | 65000 | 65000 |
2529 | CMU0976 A-III-iii-d-3 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
2530 | CMU0976 A-III-iii-d-4 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES | MEDICAL ONCOLOGY | 13600 | 13600 | 13600 | 13600 | 13600 | 13600 | 13600 | 13600 |
2531 | CMU0976 A-III-iii-e-1 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (R-CHOP) RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, +/- DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 |
2532 | CMU0976 A-III-iii-e-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
2533 | CMU0976 A-III-iv : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2534 | CMU0976 A-III-iv-a : NONHODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CDE (CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE) + RITUXIMAB - CDE (CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE) + RITUXIMAB - DAYS 1-4; CYCLOPHOSPHAMIDE 187.5-200MG/M2 IV + DOXORUBICIN 12.5MG/M2 IV + ETOPOSIDE 60MG/M2 IV, DAY 1; RITUXIMAB 375MG/M2 IV JUST BEFORE CDE REGIMEN. REPEAT CYCLE EVERY 4 WEEKS FOR A MAXIMUM OF 6 CYCLES. | MEDICAL ONCOLOGY | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 | 2600 |
2535 | CMU0976 A-III-iv-b-1 : NHL - AIDS-RELATED B-CELL LYMPHOMAS - CODOX-M ALTERNATED WITH IVAC (CODOX-M) (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE MTX ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYCLOPHOSPHAMIDE IV + DOXORUBICIN IV, DAYS 2-5; CYCLOPHOSPHAMIDE IV, DAYS 1 AND 3; CYTARABINE IT, DAYS 1 AND 8; VINCRISTINE IV, DAY 10; MTX IV OVER 1 HOUR, THEN IV INFUSION FOR 23 HOURS, DAY 11; LEUCOVORIN IV, FOLLOWED BY EVERY 6 HOURS, DAY 13; G-CSF SC DAILY UNTIL ABSOLUTE GRANULOCYTE COUNT >/=1 X 109/L, DAY 15; MTX IT, DAY 16; LEUCOVORIN 15MG ORAL, +/- DAY 1; RITUXIMAB IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS. | MEDICAL ONCOLOGY | 49100 | 49100 | 49100 | 49100 | 49100 | 49100 | 49100 | 49100 |
2536 | CMU0976 A-III-iv-b-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CODOX-M ALTERNATED WITH IVAC (IVAC) CODOX-M/IVAC (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE METHOTREXATE ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES. DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, +MESNA 360MG/M2, DAY 5; METHOTREXATE 12MG INTRATHECALLY, DAY 6; LEUCOVORIN 15MG ORALLY 24 HOURS AFTER INTRATHECAL MTX, DAY 7; G-CSF 5uG/KG SC DAILY UNTIL ABSOLUTE GRANULOCYTE COUNT >/=1 X 109/L, +/- DAY 1; RITUXIMAB 375 MG/M2 IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS. | MEDICAL ONCOLOGY | 45000 | 45000 | 45000 | 45000 | 45000 | 45000 | 45000 | 45000 |
2537 | CMU0976 A-III-iv-c-1 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 1&2) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL | MEDICAL ONCOLOGY | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 | 28100 |
2538 | CMU0976 A-III-iv-c-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 3-6) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL DAYS 1 AND 5; METHOTREXATE 12MG INTRATHECALLY. REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES | MEDICAL ONCOLOGY | 27700 | 27700 | 27700 | 27700 | 27700 | 27700 | 27700 | 27700 |
2539 | CMU0976 A-III-iv-d-1 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV | MEDICAL ONCOLOGY | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 | 62400 |
2540 | CMU0976 A-III-iv-d-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV | MEDICAL ONCOLOGY | 65000 | 65000 | 65000 | 65000 | 65000 | 65000 | 65000 | 65000 |
2541 | CMU0976 A-III-iv-d-3 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
2542 | CMU0976 A-III-iv-d-4 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES | MEDICAL ONCOLOGY | 13600 | 13600 | 13600 | 13600 | 13600 | 13600 | 13600 | 13600 |
2543 | CMU0976 A-III-iv-e-1 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, +/- DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 |
2544 | CMU0976 A-III-iv-e-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
2545 | CMU0976 A-III-v : NON HODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2546 | CMU0976 A-III-v-a-1 : NON HODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 |
2547 | CMU0976 A-III-v-a-2 : NON HODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
2548 | CMU0976 A-III-v-b : NONHODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 7 DAYS FOR 4 WEEKS | MEDICAL ONCOLOGY | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 |
2549 | CMU0976 A-III-vi : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2550 | CMU0976 A-III-vi-a-1 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - BENDAMUSTINE WITH OR WITHOUT RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1 AND 2; BENDAMUSTINE 90MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 TO 8 CYCLES | MEDICAL ONCOLOGY | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 | 31100 |
2551 | CMU0976 A-III-vi-a-2 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - BENDAMUSTINE (-) RITUXIMAB DAYS 1 AND 2; BENDAMUSTINE 90MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 TO 8 CYCLES | MEDICAL ONCOLOGY | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 |
2552 | CMU0976 A-III-vi-b-1 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 | 22800 |
2553 | CMU0976 A-III-vi-b-2 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
2554 | CMU0976 A-III-vi-c : NONHODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - CYCLOPHOSPHAMIDE + VINCRISTINE + PREDNISONE + RITUXIMAB (RCVP) - DAY 1;RITUXIMAB 375MG/M2 IV, CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 40MG/M2 ORALLY DAILY, REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES | MEDICAL ONCOLOGY | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 |
2555 | CMU0976 A-III-vi-d : NONHODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 7 DAYS FOR 4 WEEKS | MEDICAL ONCOLOGY | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 | 21700 |
2556 | CMU0976 A-III-vi-e : NONHODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - LENALIDOMIDE + RITUXIMAB - DAYS 1-21; LENALIDOMIDE 25MG ORALLY DAILY, RITUXIMAB -APPLIED SEPARATELY ON DAYS 1, 8, 15, AND 22 AS AN ADDON | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
2557 | CMU0976 A-III-vii : NONHODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2558 | CMU0976 A-III-vii-a : NON HODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA - SMILE - DAY 1; METHOTREXATE 2G/M2 IV, DAYS 2-4; DEXAMETHASONE 40MG IV OR ORALLY + LEUCOVORIN 15MG × 4 DOSES/DAY IV OR ORALLY + IFOSFAMIDE 1500MG/M2 IV + ETOPOSIDE 100MG/M2 IV, DAYS 8, 10, 12, 14, 16, 18, AND 20; L-ASPARAGINASE 6000U/M2 IV. REPEAT EVERY 21 DAYS FOR 3 CYCLES. | MEDICAL ONCOLOGY | 28900 | 28900 | 28900 | 28900 | 28900 | 28900 | 28900 | 28900 |
2559 | CMU0976 A-III-vii-b : NON HODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA - DEVIC +RT - DAY 1; CARBOPLATIN 300MG/M2, DAYS 1-3; DEXAMETHASONE 40MG IV + ETOPOSIDE 100MG/M2 IV + IFOSFAMIDE 1.5MG/M2. REPEAT CHEMOTHERAPY EVERY 3 WEEKS FOR 3 CYCLES. RADIATION 50GY AND 3 COURSES OF DEVIC | MEDICAL ONCOLOGY | 9600 | 9600 | 9600 | 9600 | 9600 | 9600 | 9600 | 9600 |
2560 | CMU0976 A-III-vii-c : NON HODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA - VIPID - DAYS 1-3; ETOPOSIDE 100MG/M2 IV OVER 90 MINUTES + IFOSFAMIDE 1200MG/M2 IV OVER 1 HOUR + CISPLATIN 33MG/M2 IV OVER 1 HOUR + DEXAMETHASONE 40MG ORALLY OR IV. REPEAT CHEMOTHERAPY EVERY 3 WEEKS FOR 3 CYCLES | MEDICAL ONCOLOGY | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 |
2561 | CMU0976 A-II-j : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CHLORAMBUCIL - DAYS 1-7; CHLORAMBUCIL 0.1MG/KG ORALLY DAILY OR 0.3MG/KG ORALLY DAILY. REPEAT EVERY 6 WEEKS. | MEDICAL ONCOLOGY | 1100 | 1100 | 1100 | 1100 | 1100 | 1100 | 1100 | 1100 |
2562 | CMU0976 A-II-k : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - FLUDARABINE - DAYS 1-5; FLUDARABINE 25MG/M2 IV DAILY. REPEAT EVERY 4 WEEKS FOR 5-6 CYCLES | MEDICAL ONCOLOGY | 12700 | 12700 | 12700 | 12700 | 12700 | 12700 | 12700 | 12700 |
2563 | CMU0976 A-II-l : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - FLUDARABINE + CYCLOPHOSPHAMIDE + RITUXIMAB (FCR) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 2-4; FLUDARABINE 25MG/M2/DAY IV +CYCLOPHOSPHAMIDE 250MG/M2/DAY IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES WITH | MEDICAL ONCOLOGY | 27600 | 27600 | 27600 | 27600 | 27600 | 27600 | 27600 | 27600 |
2564 | CMU0976 A-II-m : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - ALEMTUZUMAB - ALEMTUZUMAB DOSES GRADUALLY ESCALATED OVER 1 WEEK (3, 10, AND 30 MG), FOLLOWED BY 36 ADDITIONAL TREATMENT-PHASE INFUSIONS AT 30-MG IV 3 TIMES WEEKLY FOR 12 WEEKS. | MEDICAL ONCOLOGY | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 |
2565 | CMU0977 : MYELODYSPLASTIC SYNDROMES TREATMENT REGIMENS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2566 | CMU0977 -i : SYMPTOMATICANEMIA WITH DEL(5Q) WITH OR WITHOUT OTHER CYTOGENETIC ABNORMALITIES | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2567 | CMU0977 -i-a : SYMPTOMATIC ANEMIA WITH DEL(5Q) WITH OR WITHOUT OTHER CYTOGENETIC ABNORMALITIES - LENALIDOMIDE | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
2568 | CMU0977 -ii : SYMPTOMATICANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2569 | CMU0977 -ii-a-1 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - RHU-EPO WITH OR WITHOUT G-CSF | MEDICAL ONCOLOGY | 26300 | 26300 | 26300 | 26300 | 26300 | 26300 | 26300 | 26300 |
2570 | CMU0977 -ii-a-2 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - RHU-EPO (-) G-CSF | MEDICAL ONCOLOGY | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 | 26000 |
2571 | CMU0977 -ii-b-1 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - DARBEPOETIN ALFA WITH OR WITHOUT G-CSF | MEDICAL ONCOLOGY | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 |
2572 | CMU0977 -ii-b-2 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - DARBEPOETIN ALFA (-) G-CSF | MEDICAL ONCOLOGY | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 |
2573 | CMU0977 -iii : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2574 | CMU0977 -iii-a-1 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST - DECITABINE (15MG/M2) | MEDICAL ONCOLOGY | 16300 | 16300 | 16300 | 16300 | 16300 | 16300 | 16300 | 16300 |
2575 | CMU0977 -iii-a-2 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST - DECITABINE (20MG/M2) | MEDICAL ONCOLOGY | 17300 | 17300 | 17300 | 17300 | 17300 | 17300 | 17300 | 17300 |
2576 | CMU0977 -iii-b : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST - LENALIDOMIDE | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
2577 | CMU0978 : MULTIPLE MYELOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2578 | CMU0978 -a : MULTIPLE MYELOMA - LENALIDOMIDE (28 DAYS) + DEXAMETHASONE | MEDICAL ONCOLOGY | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 |
2579 | CMU0978 -b : MULTIPLE MYELOMA - LENALIDOMIDE (21 DAYS) + DEXAMETHASONE | MEDICAL ONCOLOGY | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 |
2580 | CMU0978 -c : MULTIPLE MYELOMA - LENALIDOMIDE | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
2581 | CMU0978 -d : MULTIPLE MYELOMA - BENDAMUSTINE + LENALIDOMIDE + DEXAMETHASONE | MEDICAL ONCOLOGY | 14300 | 14300 | 14300 | 14300 | 14300 | 14300 | 14300 | 14300 |
2582 | CMU0978 -e : MULTIPLE MYELOMA - BENDAMUSTINE | MEDICAL ONCOLOGY | 23100 | 23100 | 23100 | 23100 | 23100 | 23100 | 23100 | 23100 |
2583 | CMU0978 -f : MULTIPLE MYELOMA - CYCLOPHOSPHAMIDE + LENALIDOMIDE + DEXAMETHASONE | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
2584 | CMU0978 -g : MULTIPLE MYELOMA - DEXAMETHASONE + CYCLOPHOSPHAMIDE + ETOPOSIDE + CISPLATIN (DCEP) | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
2585 | CMU0978 -h : MULTIPLE MYELOMA - DEXAMETHASONE + THALIDOMIDE + CISPLATIN + DOXORUBICIN + CYCLOPHOSPHAMIDE + ETOPOSIDE (DT-PACE) | MEDICAL ONCOLOGY | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 |
2586 | CMU0978 -i : MULTIPLE MYELOMA - HIGH-DOSE CYCLOPHOSPHAMIDE | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
2587 | CMU0978 -j : MULTIPLE MYELOMA - VAD / VAMP | MEDICAL ONCOLOGY | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 |
2588 | CMU0978 -k : MULTIPLE MYELOMA - MELPHALAN | MEDICAL ONCOLOGY | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 |
2589 | CMU0978 -l : MULTIPLE MYELOMA - MELPHALAN + PREDNISOLONE | MEDICAL ONCOLOGY | 1200 | 1200 | 1200 | 1200 | 1200 | 1200 | 1200 | 1200 |
2590 | CMU0978 -m : MULTIPLE MYELOMA - THALIDOMIDE + DEXAMETHASONE | MEDICAL ONCOLOGY | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
2591 | CMU0978 -n : MULTIPLE MYELOMA - MELPHALAN / PREDNISOLONE/THALIDOMIDE(MPT) | MEDICAL ONCOLOGY | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 |
2592 | CMU0978 -O : MULTIPLE MYELOMA - ZOLEDRONIC ACID | MEDICAL ONCOLOGY | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 |
2593 | CMU0979 : ALL LYMPHOMA SALVAGE CHEMO (PACKAGE 953 TO BE UTILISED) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2594 | CMU0980 : CHILDHOOD B CELL LYMPHOMA VARIABLE REGIMEN (PACKAGE 953 TO BE UTILISED) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2637 | CMU1010 : HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY | MEDICAL ONCOLOGY | 100000 | 100000 | 100000 | 100000 | 100000 | 100000 | 100000 | 100000 |
2638 | CMU1011 : HYPERTHERMIC INTRAPERITONEAL CATHETER INSERTION | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
2645 | CMU1018 : CHEMOPORT - DEVICE WITH ACESSORIES AND MAINTENCE | MEDICAL ONCOLOGY | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 |
2647 | CMU1020 : HEMATOLOGICAL AND ONCOLOGICAL EMERGENCIES ( SUPERIOR MEDIASTINAL SYNDROME, SUPERIOR VENA CAVA SYNDROME, HYPER LEUCOCYTOSIS, HYPERVISCOSITY DUE TO DYSPROTEINEMIA, VASO-OCCLUSIVE CRISIS) | MEDICAL ONCOLOGY | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 |
2648 | CMU1021 : TUMOURLYSIS SYNDROME ( DRUGS AND MANAGEMENT WITHOUT DIALYSIS) | MEDICAL ONCOLOGY | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 |
2655 | CMU1028 : INTRATHECAL CHEMOTHERAPY | MEDICAL ONCOLOGY | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 |
3295 | CM1419 : Acute lymphoblastic leukemia: Supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3296 | CM1420 : Acute myeloid leukemia: Supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3297 | CM1421 : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3298 | CM1422 : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3299 | CM1423 : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3300 | CM1424 : Retinoblastoma (Intraocular): supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3301 | CM1425 : Retinoblastoma (extraocular): supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3302 | CM1426 : Brain tumors: supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3303 | CM1427 : Histiocytosis: supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3304 | CM1428 : Bone tumors/soft tissue sarcomas : supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3305 | CM1429 : Chronic Myeloid Leukemia : supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3306 | CM1430 : Terminally IllPalliative And Supportive Therapy - Per month | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3376 | CM1419 A : Acute lymphoblastic leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | MEDICAL ONCOLOGY | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 |
3377 | CM1420 A : Acute myeloid leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage | MEDICAL ONCOLOGY | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 |
3378 | CM1421 A : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | MEDICAL ONCOLOGY | 15000 | 15000 | 15000 | 15000 | 15000 | 15000 | 15000 | 15000 |
3379 | CM1422 A : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | MEDICAL ONCOLOGY | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 |
3380 | CM1423 A : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | MEDICAL ONCOLOGY | 50000 | 50000 | 50000 | 50000 | 50000 | 50000 | 50000 | 50000 |
3381 | CM1429 A : Chronic Myeloid Leukemia : supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | MEDICAL ONCOLOGY | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 |
3382 | CM1430 A : Terminally Ill - Pain management (Opioid therapy / Neural Blocks / epidural or Intrathecal infusions / Antero-lateral spinal cordotomy (tractotomy) by RFA) / TPN - Per month | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |